

BMJ Open

Swabbing methods for estimating the prevalence of bacterial carriage in the upper respiratory tract: a cross sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005341
Article Type:	Research
Date Submitted by the Author:	25-Mar-2014
Complete List of Authors:	Coughtrie, Abigail; University of Southampton, Faculty of Medicine Whittaker, Robert; University of Southampton, Faculty of Medicine Begum, Nelupha; University of Southampton, Faculty of Medicine Anderson, Rebecca; University of Southampton, Faculty of Medicine Tuck, Andy; University of Southampton, Faculty of Medicine Faust, Saul; University of Southampton, Faculty of Medicine Jefferies, Johanna; University of Southampton, Faculty of Medicine Yuen, Ho Ming; University of Southampton, Faculty of Medicine Roderick, Paul; University of Southampton, Faculty of Medicine Mullee, Mark; University of Southampton, Faculty of Medicine Moore, Michael; University of Southampton, Faculty of Medicine Clarke, Stuart; University of Southampton, Faculty of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Respiratory medicine, Infectious diseases
Keywords:	Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES, Diagnostic microbiology < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3 Swabbing methods for estimating the prevalence of bacterial
4
5
6 carriage in the upper respiratory tract: a cross sectional study
7
8
9
10

11
12 A L Coughtrie ¹, R N Whittaker ¹, N Begum ¹; R Anderson ¹; A Tuck ¹; S N Faust ^{1,2,3}; J M Jefferies ^{1,3}; H
13
14 M Yuen ¹; P J Roderick ¹; M A Mullee ^{1,4}; M V Moore ¹; S C Clarke ^{1,3,5}
15
16
17
18
19

20 ¹Faculty of Medicine and Institute for Life Sciences, University of Southampton, UK; ²Southampton
21
22 NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton Foundation NHS
23
24 Trust, Southampton, UK; ³Southampton NIHR Respiratory Biomedical Research Unit, University
25
26 Hospital Southampton Foundation NHS Trust, Southampton, UK; ⁴NIHR Research Design Service
27
28 South Central, University Hospital Southampton Foundation NHS Trust, Southampton, UK; ⁵Public
29
30 Health England, Southampton, UK;
31
32
33
34

35 Correspondence to:

36
37 Dr Stuart C. Clarke
38

39 Infectious Disease Epidemiology Group, University of Southampton, Mailpoint 814, Level C, South
40
41 Block, University Hospital Southampton Foundation NHS Trust, Southampton SO16 6YD, UK
42
43

44 S.C.Clarke@southampton.ac.uk
45
46
47

48 Running Title:

49 Swabbing methods for the estimation of respiratory bacterial carriage
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives. Bacterial carriage in the upper respiratory tract leads to respiratory tract infection (RTI), meningitis and septicaemia. We aimed to provide a baseline measure of *Streptococcus pneumoniae*, *Moraxella catarrhalis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Haemophilus influenzae* and *Neisseria meningitidis* carriage within the community. Self-swabbing, via nose (NS) and whole mouth swabs (WMS), and Healthcare professional (HCP) swabbing, via nasopharyngeal (NPS) and WMS, were compared.

Design. Cross-sectional study.

Setting. Patients registered at 20 general practitioner (GP) practices within the Wessex Primary Care Research Network South East hub, United Kingdom.

Participants. 10,448 patients were randomly selected to undertake either self-swabbing or HCP swabbing; 202 young children and 320 older children and adults from each GP practice. Patients deemed unfit for participation by their GP were excluded.

Results. 1,574 (15.1%) patients participated, 1,260 (23.4%, 95% CI 22.3%–24.5%) undertaking self-swabbing and 314 (6.2%, 95% CI 5.5%–6.9%) undertaking HCP-led swabbing. Participation was lower in young children and in more deprived practice locations. Swab positivity rates were 34.8% (95% CI 32.2%–37.5%) for NS, 19.6% (95% CI 17.4%–21.8%) for self-taken WMS, 27.4% (95% CI 22.5%–32.3%) for NPS and 34.1% (95% CI 28.8%–39.3%) for HCP-taken WMS. Carriage rates of *S. aureus* were highest in NS (21.3%). *S. pneumoniae* carriage was highest in NS (11.0%) and NPS (7.3%). *M. catarrhalis* carriage was highest in HCP-taken WMS (30.3%). *H. influenzae* and *P. aeruginosa* carriage were similar between swab types. *N. meningitidis* was not detected in any swab. Age and recent RTI affected carriage of *S. pneumoniae* and *H. influenzae*. Participant costs were lower for self-swabbing (£41.21) versus HCP swabbing (£69.66).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions. Higher participation and lower costs of self-swabbing and higher sensitivity of nose swabs favour this method for use in future, large population-based respiratory carriage studies.

For peer review only

Strengths and limitations of this study

- This study is the largest community-based swabbing study to date to report carriage rates of multiple bacterial species simultaneously.
- This study provides important evidence for the use of nose swabs for detection of *Streptococcus pneumoniae* and other respiratory pathogens.
- Non-response bias needs to be considered within both self-swabbing and HCP swabbing groups.

For peer review only

INTRODUCTION

The respiratory tract is host to a wide variety of commensal and pathogenic microorganisms, with approximately 250 species colonising the nasopharynx alone [1]. Asymptomatic carriage in the upper respiratory tract (URT) is the first stage in the process of RTI, meningitis and sepsis. Carriage often occurs without disease but may also lead to serious invasive illness [2, 3]. In 2010, approximately 4.4 million deaths worldwide resulted from an RTI, most commonly in young children [4].

Collecting samples from the URT enables the estimation of carriage rates of pathogenic organisms. The determination of carriage rates is essential for assessing circulating respiratory microbes which may go on to cause disease. A number of sites within the URT have been used to assess carriage, including the nasopharynx, oropharynx, nose and throat. Methods for assessing carriage have included swabbing, nose blowing and nasopharyngeal aspiration [5-12]. However, no single study has evaluated the use of different swabbing methods using a large population-based sample. *S. pneumoniae* remains the only bacterial species for which a WHO standard method has been established for detecting carriage [13]. It is currently recommended to take a nasopharyngeal swab despite the other sites being equally as effective, if not more sensitive, in assessing carriage of this organism [7, 10]. Self-swabbing has also been shown to be effective in assessing nasal carriage of *S. aureus* and viruses and offers a cheaper alternative to more traditional healthcare professional (HCP) swabbing [12, 14].

Most carriage studies have focused on a particular organism and participant age group. However, many microorganisms are thought to play a role in RTI development and carriage in all age groups is important in terms of understanding disease transmission and immunity against specific pathogens [15]. Moreover, in the current vaccine era, we are likely to see an explosion of new vaccines during the coming decade that will affect the respiratory tract microbiota [16-20]. This highlights the need for large population-based studies which include all age groups and aim to detect as many relevant microbial species as possible.

1
2
3 Our study aimed to provide a baseline measure for understanding multi-species bacterial carriage in
4 the respiratory tract within the general population of one geographical area of the UK. The
5 objectives were to assess the optimal sample collection method and site by comparing self-taken
6 nose and mouth swabs with HCP-taken nasopharyngeal and mouth swabs; to gain an estimate of
7 participant consent rates in both study groups and to test the feasibility of conducting a larger multi-
8 site investigation. Finally, the study aimed to estimate carriage rates of relevant URT bacterial
9 species. This would help inform samples sizes for multi-centre studies, particularly for use in pre-
10 and post-vaccine studies, as well as to aid in understanding the effects of demographic factors and
11 deprivation on carriage.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Sample Size

This was a pilot study and not designed to have the power to detect non-inferiority of estimating carriage rates by HCP-administered versus self-administered swabs. Data from this study was predicted to inform sample sizes required for future large carriage studies. The sample size for this pilot study was based on the precision with which we can estimate true carriage rates. A 25% response rate among self-swabbing participants was assumed based on results from a previous staphylococcal carriage study [12]. A 25% response rate was also assumed for HCP-swabbing.

We invited 2,020 children aged 0-4 years and 3,200 older children and adults to participate, anticipating 505 children and 800 older children/adult responders, accounting for predicted lower carriage rates in older children and adults. A predicted carriage rate of 30% in 505 participating children would enable the determination of true carriage to within $\pm 4.0\%$ (95% confidence) [21]. A predicted carriage rate of 20% in 800 participating older children and adults would enable the determination of true carriage to within $\pm 2.8\%$ (95% confidence) [9].

Participant Recruitment

Participants were selected from twenty general practitioner (GP) practices within the Wessex Primary Care Research Network (PCRN) South East hub area, in Southern England. GP practices were chosen to reflect a mix of urban/rural locations, practice sizes and area deprivation levels. Each GP practice produced a list of their entire patient cohort. Any patient deemed unfit for participation by their GP, for example due to terminal illness or serious mental health problems, was removed from the list. From each GP list, 202 patients aged 0-4 years and 320 patients aged ≥ 5 years were randomly selected and allocated to one of two study groups using the *ralloc* command in Stata 12.

1
2
3 The HCP group involved participants being invited, via letter, to organise a swabbing appointment at
4 their GP practice where nasopharyngeal (NPS) and whole mouth (WMS) swabs were taken by a
5 registered HCP. The self-swabbing group involved participants being sent a self-swabbing pack
6 containing nose (NS) and whole mouth (WMS) swabs by Danvers International (London, UK). WMS
7 were used as a proxy for throat swabs, as the latter are difficult and uncomfortable to self-perform.
8
9

10
11 Each participant was given an age-appropriate information sheet explaining the study aims.
12
13 Participants were asked to complete a consent form and questionnaire, provided either at their
14 swabbing appointment or within their self-swabbing pack. The study questionnaire requested the
15 following details pertinent to bacterial carriage: participant age, recent use of antibiotics, recent RTI
16 and vaccination status. Age was split into the following groups for analysis: 0-4 years, 5-17 years, 18-
17 64 years and 65 years and older due to the relevance of each of these age groups in carriage of the
18 different bacterial species. Recent use of antibiotics and recent were split into the following groups
19 for analysis: yes, no and do not know/missing. Vaccination status was split into the following groups
20 for analysis: up-to-date, not up-to-date and do not know/missing. UK Index of Multiple Deprivation
21 (IMD) 2010 scores were obtained for each GP practice based on the Lower layer Super Output Area
22 (LSOA) it was located in and was used as a proxy for deprivation of each practices' patient
23 population [22]. This would enable the relationship between carriage and deprivation to be assessed,
24 as in disease studies [23]. A total of 10,448 patients were invited to participate in the study,
25 approximately 526 patients/practice.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Sample Collection and Analysis**

49
50
51 Participants were invited to undertake swabbing between May-August 2012. Swabs were returned
52 either via first-class freepost return (self-swabbing group) or pre-existing NHS delivery service or taxi
53 (HCP group). Upon receipt, swabs were immersed in skim milk, tryptone, glucose and glycerine
54
55
56
57
58
59
60

1
2
3 (STGG) storage media, vigorously rubbed against the side of the tube and vortexed to ensure
4 transfer of bacteria into the STGG. Standard microbiology culture and identification techniques were
5 used to analyse the swab contents for the presence of *S. pneumoniae*, *H. influenzae*, *M. catarrhalis*,
6
7 *S. aureus*, *P. aeruginosa* and *N. meningitidis* (Supplementary Table 1) before being frozen for future
8
9 use at -70°C.
10
11
12

13 14 **Statistical Analysis**

15 Culture data and participant questionnaire information were tabulated into SPSS (v20) for analysis.
16
17 Missing or incomplete data was classed as missing within the SPSS variables window. Participation
18 rates, the proportion of participants relative to total number of patients invited, were calculated for
19 each GP practice and age group. UK IMD 2010 scores for each GP practice area were examined in
20 relation to participation rates using Pearson's Correlation. Swab positivity rates, the proportion of
21 swabs that isolated any of the target bacteria relative to total swab numbers, were calculated for
22 each swab type. Confidence Intervals (95% CI) were calculated to assess reliability of participation
23 and positivity rates.
24
25
26
27
28
29
30
31
32
33

34 Carriage rates, the proportion of a specific bacterial species relative to total number of swabs, were
35 calculated according to swab type, age, recent RTI, recent antibiotic use, vaccination status,
36 geographical location and deprivation. Chi-squared and Fisher's Exact tests were used to determine
37 any associations between carriage and these variables. Geographical mapping of carriage rates was
38 performed using ArcGIS (ESRI, v10.1) [24]. Practices were grouped into geographical areas for
39 statistical analysis based on proximity to one another. Finally, co-carriage rates, the proportion of
40 samples containing multiple bacterial species relative to total number of swabs, were calculated
41 according to swab type, age, recent RTI, recent antibiotic use, vaccination status and geographical
42 location.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study Costs

Total costs associated with each swabbing method were calculated to allow cost comparisons between methods. Costs were separated into laboratory consumables, printing, swabs, National Health Service (NHS) Service Support Costs (additional healthcare costs due to the research taking place), transport and postage.

For peer review only

RESULTS

Participation Rates

Eighteen of the 20 GP practices participated in both self- and HCP-swabbing, one participated in self-swabbing only and one dropped out of the study. Participant characteristics are shown in table 1. Overall participation rates were higher in the self-swabbing group at 23.4% ($n=1,260$, 95% CI 22.3%–24.5%) compared with the HCP group at 6.2% ($n=314$, 95% CI 5.5%–6.9%). Self-swabbing participation rates varied from 9.3% ($n=27$) to 33.1% ($n=96$) between practices whereas HCP participation rates varied from 1.0% ($n=3$) to 12.3% ($n=34$). Ten practices had participation rates $\geq 25\%$ in the self-swabbing group, which was the anticipated level of participation. There was a negative correlation between participation rate and deprivation score in the self-swabbing group ($r=-0.473$, $p=0.041$) and the HCP group ($r=-0.417$, $p=0.085$), which was only significant in the former. Participation was higher in individuals aged ≥ 5 years at 27.8% ($n=931$) in the self-swabbing group and 8.2% ($n=258$) in the HCP group versus 0-4 years at 16.1% ($n=329$) in the self-swabbing group and 2.9% ($n=56$) in the HCP group. The greatest number of responses received was from individuals aged 50-80 years, comprising 41.7% ($n=656$) of total participants.

Swab Positivity Rates

Overall the proportion of swabs positive for any one of the six bacterial species (positivity rate) in both study groups was similar at 47.2% ($n=595$) in the self-swabbing group and 48.4% ($n=152$) in the HCP group. Swab positivity rates were 34.8% (95% CI 32.2%–37.5%) for NS, 19.6% (95% CI 17.4%–21.8%) for self-taken WMS, 27.4% (95% CI 22.5%–32.3%) for NPS and 34.1% (95% CI 28.8%–39.3%) for HCP-taken WMS (Supplementary Figure 1). The nose swab (NS) and HCP-taken WMS were most effective in detecting carriage of the target organisms. Positivity rates of self-taken WMS and HCP-taken WMS were significantly different ($\chi^2=35.57$, $df=1$, $p<0.001$).

Bacterial Carriage Rates

Culture data, in Figure 1, showed significantly greater carriage of *S. aureus* in NS than any other swab type. *S. pneumoniae* carriage was detected similarly in NS and NPS, which was significantly greater than either WMS. Although *H. influenzae* carriage was highest in NS, this was not significantly different from the other swab types. *M. catarrhalis* carriage was significantly higher in the HCP-taken WMS when compared with the other swab types. *P. aeruginosa* carriage was higher in the self-taken WMS but was not significantly different from the other swab types. *N. meningitidis* was not detected in any swab type used in this study.

We sought to compare the carriage rates of the bacterial species in each swab type. These were similar between NS/NPS and between the two WMS, except for *M. catarrhalis* carriage, which differed significantly between the two WMS in most age groups, and *S. aureus*, which showed significant differences between NS/NPS in individuals aged 18-64 years (Table 4).

Co-carriage Rates

Overall co-carriage rates were 3.9% ($n=49$) in NS, 1.0% ($n=13$) in self-taken WMS, 2.3% ($n=7$) in NPS and 1.9% ($n=6$) in HCP-taken WMS. In NS and NPS, co-carriage rates were significantly higher in individuals aged 0-4 years (NS [9.1%, $n=30$] and NPS [8.9%, $n=5$]) versus ≥ 5 years (NS [2.1%, $n=19$] and NPS [0.8%, $n=2$]). Nose co-colonisation decreased with age, with 8.0% ($n=11$) in individuals aged 5-17 years, 1.1% ($n=5$) in individuals aged 18-64 years and 1.0% ($n=3$) in those aged ≥ 65 years. The most common co-colonisation relationship in nose swabs was *S. pneumoniae-H. influenzae* (50% [$n=15$] in 0-5 years, 26.3% [$n=5$] in ≥ 5 years).

Association between Demographics and Carriage

Participant age

Bacterial carriage was highly variable with age, in particular carriage of *S. pneumoniae*, *H. influenzae* and *S. aureus* (Tables 2-3). *S. pneumoniae* and *H. influenzae* carriage decreased with age, with 0-4 year olds experiencing the highest carriage rates. *S. pneumoniae* nasal carriage was >2x higher in 0-4 year olds compared with those aged 5-17 years. *H. influenzae* nasal carriage decreased more steadily with age. *S. aureus* carriage increased sharply in young children but remained high after the age of five. *S. aureus* carriage was >3x higher in participants aged 5-17 years when compared with participants 0-4 years. *M. catarrhalis* and *P. aeruginosa* were less variable between the age groups.

Participant questionnaire information

Higher nasal carriage rates of *S. pneumoniae* and *H. influenzae* were observed in participants who had experienced a recent RTI. *S. pneumoniae* carriage was >3x higher in those with recent RTI versus those without recent RTI, using the Fisher's Exact test ($\chi^2=66.408$, $df=1$, $p<0.001$). *H. influenzae* nasal carriage was also higher in those with recent RTI versus those without recent RTI, using the Chi-squared test ($\chi^2=12.533$, $df=1$, $p=0.001$). Recent antibiotic treatment and up-to-date vaccination status were not associated with significant changes in carriage of the target bacteria. Full results and *p*-values are shown in Tables 2-3. In NS, recent RTI was also associated with higher co-carriage rates at 8.0% ($n=29$) when compared with no recent RTI at 2.2% ($n=19$). Recent antibiotic use, vaccination status and geographical location did not appear to affect co-carriage rates.

Geographical location

Carriage rates of the target bacterial species showed some differences according to practice location (Supplementary Figure 2). Overall bacterial carriage was significantly different by geographical area in NS ($\chi^2=11.609$, $df=5$, $p=0.04$) and self-taken WMS ($\chi^2=13.900$, $df=5$, $p=0.02$) but not in either HCP swab. However, individual bacteria carriage rates were not significantly different between geographical areas.

Deprivation

Participants attending practices in less deprived locations had slightly higher bacterial carriage rates, except for *P. aeruginosa*, suggesting a possible negative relationship between deprivation score and bacterial carriage. However the differences observed were not statistically significant.

Study Costs

Overall, total costs per participant were over a third lower in the self-swabbing group at £41.21 (\$67.92) versus the HCP group at £69.66 (\$114.82) (Table 1). NHS service support costs made up a large proportion of the difference between the two study groups, representing 56.7% (£39.52/person) of costs in the HCP group but only 6.8% (£2.81/person) of costs in the self-swabbing group.

DISCUSSION

Few studies have simultaneously described the carriage rates of multiple bacterial species within the respiratory tract and, to our knowledge, none have reported bacterial carriage in a large population-based study across all age groups. This study aimed to address this information gap in order to generate greater insight into the complexities of microbial respiratory carriage. This involved undertaking a large community-based respiratory tract carriage study by recruiting participants from 20 GP practices from a single geographical area in Southern England. Different studies have previously reported carriage rates from divergent swabbing sites, making comparisons between these studies difficult. We compared multiple swabbing sites in order to assess the most effective way of sampling the human respiratory tract flora in the hope to provide information for implementation of a standardised swabbing method.

Higher participation rates within the self-swabbing group compared with the HCP group highlight the willingness of patients to participate in such studies when the process is facilitated. The very low participation rate of the HCP group would render this method invalid for large-scale studies. Whilst the responsiveness of the self-swabbing group was higher, it was still less than 25%, meaning there will always be a problem of non-response bias. Barriers to participation in the HCP group might include the amount of time required for organising and attending swabbing appointments and the slight discomfort experienced during nasopharyngeal swabbing. Self-swabbing overcame many of these barriers by offering a relatively straightforward, rapid and easy alternative. High participation rates in elderly participants might be a result of their increased availability for participation and their increased chance of exposure to RTI allowing them to relate to the study aims. Younger participants, on the other hand, may have a different attitude towards participation. Parents may also be reluctant to swab their children if they are very young. The negative correlation between participation rates and deprivation highlights certain barriers associated with high levels of deprivation, which have been observed in other studies [25].

1
2
3 Swab positivity rates and bacterial carriage rates indicate that the NS was most sensitive in sampling
4 microbial species within the airways of the general population within our large population-based
5 study. Although HCP-swabbing was highly sensitive, as demonstrated by a significantly higher
6 positivity rate for HCP-taken WMS versus self-taken WMS, lower participation rates within this
7 group have most probably resulted in reduced carriage rates within NPS. Very low participation rates
8 in the HCP group are problematic for assessing carriage within the general population as fewer
9 numbers of samples can be obtained and the cost of obtaining them is high. These high costs are
10 mainly due to the operation of swabbing clinics. In order to increase participation, healthcare
11 providers could undertake verbal encouragement or study advertisement in practice. WMS were
12 efficient in isolating *M. catarrhalis* and *P. aeruginosa*, however, large amounts of background flora
13 within this site and low isolation levels for the other bacteria render this swab less efficient on the
14 whole. The lack of isolation of *N. meningitidis* may be due to the type of swabs used, as
15 oropharyngeal swabs are often preferred [26]. Low response rates from teenagers, the most
16 frequent carriers of *N. meningitidis*, may also have caused the lack of isolation of this species [27].
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Carriage rates of five out of the six target organisms follow previously observed patterns with *S.*
35 *pneumoniae* and *H. influenzae* being carried predominantly in young children and *S. aureus* being
36 carried more in older children and adults [12, 28, 29]. *M. catarrhalis* and *P. aeruginosa* carriage rates
37 were constant across all age groups demonstrating that carriage of these organisms is unaffected by
38 age. *N. meningitidis* carriage did not follow previously observed patterns as no isolates were
39 detected. However, the number of participants in the study may not have been large enough to
40 detect any isolates with 95% confidence. The effect of recent RTI on carriage of *S. pneumoniae* and *H.*
41 *influenzae* is one that might be expected as colds and flu weaken host immunity allowing for carriage
42 by these organisms [30]. The lack of an apparent effect of vaccination status is potentially due to
43 herd immunity, as unvaccinated people benefit from protection from disease as a result of a largely
44 vaccinated population. Access to individual participant immunisation records in future studies might
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 enable improved assessment of the effects of immunisation on carriage of target and non-target
4
5 bacteria.
6
7

8 The results from this pilot study have allowed the comparison of swabbing methodologies for
9
10 determining carriage of the targeted bacterial species within the respiratory tract. The advantages of
11
12 self-swabbing are evident with higher responsiveness and lower costs than HCP swabbing. Further
13
14 assessment will determine whether our findings are applicable to other geographical locations, over
15
16 time and to a wider array of bacterial species. Such assessment would help to refine methodologies,
17
18 which will be key to obtaining a precise understanding of bacterial carriage in the respiratory tract.
19
20 By determining carriage rates in different age groups, the study has enabled the determination of at-
21
22 risk populations which is key to developing efficient vaccination and antibiotic strategies.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding

This work was supported by the Rosetrees Trust [M141 to S.C.C.] and the Bupa Foundation [TBF-M11-019 to S.C.C.].

Conflicts of Interest

S.N.F. receives support from the National Institute for Health Research funding via the Southampton NIHR Wellcome Trust Clinical Research Facility and the Southampton NIHR Respiratory Biomedical Research Unit. J.M.J. has received consulting fees from GlaxoSmithKline. S.N.F. acts as principal investigator for clinical trials conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receives no personal payments from them. S.N.F. has participated in advisory boards for vaccine manufacturers but receives no personal payments for this work. S.C.C. currently receives unrestricted research funding from Pfizer Vaccines (previously Wyeth Vaccines) and has participated in advisory boards and expert panels for GSK, Pfizer and Novartis. S.C.C. is an investigator on studies conducted on behalf of University Hospital Southampton NHS Foundation Trust / University of Southampton / Public Health England that are sponsored by vaccine manufacturers but receives no personal payments from them. S.N.F., S.C.C. and J.M.J. have received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. All other authors have no conflicts of interest.

Author Contributions and Acknowledgments

ALC: Study set-up, data collection, data analysis and writing; RNW: Study set-up, data collection, proof-reading of manuscript; NB: Data collection, proof-reading of manuscript; RA: Data collection, proof-reading of manuscript; AT: Study design, data collection, proof-reading of manuscript; SNF: Study design, data analysis, proof-reading of manuscript; JMJ: Study design, data analysis, proof-

1
2
3 reading of manuscript; HMY: Study design, data analysis, proof-reading of manuscript; PJR: Study
4
5 design, data analysis, proof-reading of manuscript; MAM: Study design, data analysis, proof-reading
6
7 of manuscript; MVM: Study design, data analysis, proof-reading of manuscript; SCC: Study design,
8
9 data collection, data analysis, proof-reading of manuscript.
10

11
12 We thank Shabana Hussain for technical assistance throughout the study. We also thank the Bupa
13
14 Foundation for providing the funding to SCC in order to undertake the study and the Rosetrees Trust
15
16 for their funding contribution for ALC's PhD studentship. We thank the Southampton NIHR
17
18 Wellcome Trust Clinical Research Facility for part-funding SNF. We also thank the National Institute
19
20 for Health Research Comprehensive Local Research Network (NIHR CLRN), NHS Service Support
21
22 Costs, Solent Primary Care Trust (PCT), South West (East Hub) Primary Care Research Network (PCRN)
23
24 and Danvers International for their contributions.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bogaert, D., et al., *Variability and diversity of nasopharyngeal microbiota in children: a metagenomic analysis*. PLoS One, **2011**. 6(2): p. e17035.
2. Faden, H., et al., *Relationship between Nasopharyngeal Colonization and the Development of Otitis Media in Children*. J Infect Dis, **1997**. 175: p. 1440-1445.
3. Brueggemann, A.B., et al., *Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential*. J Infect Dis, **2003**. 187(9): p. 1424-32.
4. Lozano, R., et al., *Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010*. Lancet, **2012**. 380(9859): p. 2095-128.
5. Akmatov, M.K., et al., *E-mail-based symptomatic surveillance combined with self-collection of nasal swabs: a new tool for acute respiratory infection epidemiology*. Int J Infect Dis, **2011**. 15(11): p. e799-803.
6. Leach, A.J., et al., *Comparison of nasal swabs with nose blowing for community-based pneumococcal surveillance of healthy children*. J Clin Microbiol, **2008**. 46(6): p. 2081-2.
7. Lieberman, D., et al., *Nasopharyngeal versus oropharyngeal sampling for isolation of potential respiratory pathogens in adults*. J Clin Microbiol, **2006**. 44(2): p. 525-8.
8. Trotter, C.L. and N.J. Gay, *Analysis of longitudinal bacterial carriage studies accounting for sensitivity of swabbing: an application to Neisseria meningitidis*. Epidemiol Infect, **2003**. 130(2): p. 201-205.
9. Watt, J.P., et al., *Nasopharyngeal versus oropharyngeal sampling for detection of pneumococcal carriage in adults*. J Clin Microbiol, **2004**. 42(11): p. 4974-6.
10. Rapola, S., et al., *Comparison of Four Different Sampling Methods for Detecting Pharyngeal Carriage of Streptococcus pneumoniae and Haemophilus influenzae in Children*. J Clin Microbiol, **1997**. 35(5): p. 1077-1079.
11. Greenberg, D., et al., *Relative importance of nasopharyngeal versus oropharyngeal sampling for isolation of Streptococcus pneumoniae and Haemophilus influenzae from healthy and sick individuals varies with age*. J Clin Microbiol, **2004**. 42(10): p. 4604-9.
12. Gamblin, J., et al., *Nasal self-swabbing for estimating the prevalence of Staphylococcus aureus in the community*. J Med Microbiol, **2013**. 62(Pt 3): p. 437-40.
13. O'Brien, K.L. and H. Nohynek, *Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae*. Pediatr Infect Dis J, **2003**. 22(2): p. e1-11.
14. Akmatov, M.K., et al., *Equivalence of self- and staff-collected nasal swabs for the detection of viral respiratory pathogens*. PLoS One, **2012**. 7(11): p. e48508.
15. de Roux, A., et al., *Mixed community-acquired pneumonia in hospitalised patients*. Eur Respir J, **2006**. 27(4): p. 795-800.
16. Harro, C.D., et al., *The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies*. Vaccine, **2012**. 30(9): p. 1729-36.
17. Moore, R., et al., *Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection*. Hum Vaccin Immunother, **2012**. 9(3): p. Published ahead of print.
18. Serruto, D., et al., *The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens*. Vaccine, **2012**. 30 Suppl 2: p. B87-97.
19. Sheldon, E., et al., *A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults*. Hum Vaccin Immunother, **2012**. 8(7): p. 888-895.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
20. Skinner, J.M., et al., *Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model*. *Vaccine*, **2011**. 29(48): p. 8870-6.
21. Tocheva, A.S., et al., *Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of *Streptococcus pneumoniae* in young children*. *Vaccine*, **2011**. 29(26): p. 4400-4.
22. Government, D.f.C.a.L., *English indices of deprivation 2010*, Department for Communities and Local Government, Editor. **2011**: London, UK.
23. Chapman, K.E., D. Wilson, and R. Gorton, *Invasive pneumococcal disease and socioeconomic deprivation: a population study from the North East of England*. *J Public Health (Oxf)*, **2013**. 35(4): p. 558-69.
24. ESRI, *ArcGIS 10.1*. **2012**, ESRI: Redlands, California.
25. Sheron, N., et al., *Feasibility of detection and intervention for alcohol-related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS)*. *Br J Gen Pract*, **2013**. 63(615): p. e698-705.
26. Olcen, P., et al., *Culture diagnosis of meningococcal carriers: yield from different sites and influence of storage in transport medium*. *J Clin Pathol*, **1979**. 32(12): p. 1222-5.
27. Cartwright, K.A., et al., *The Stonehouse survey: nasopharyngeal carriage of meningococci and *Neisseria lactamica**. *Epidemiol Infect*, **1987**. 99(3): p. 591-601.
28. Gray, B.M., G.M. Converse, 3rd, and H.C. Dillon, Jr., *Epidemiologic studies of *Streptococcus pneumoniae* in infants: acquisition, carriage, and infection during the first 24 months of life*. *J Infect Dis*, **1980**. 142(6): p. 923-33.
29. Peltola, H., T. Kilpi, and M. Anttila, *Rapid disappearance of *Haemophilus influenzae* type b meningitis after routine childhood immunisation with conjugate vaccines*. *Lancet*, **1992**. 340(8819): p. 592-4.
30. Brundage, J.F., *Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness*. *Lancet Infect Dis*, **2006**. 6(5): p. 303-312.

Table 1. Participant Characteristics and Study Costs (in British Pounds) for Self-swabbing and HCP swabbing

	Participant characteristics n(%) and costs per participant (£)	
	Self-swabbing	HCP swabbing
Age (years)		
Mean	37.42	50.09
Minimum	0	0
Maximum	94	88
0-4	329 (26.1)	56 (17.8)
5-17	137 (10.9)	24 (7.6)
18-64	465 (36.9)	89 (28.3)
65+	311 (24.7)	145 (46.2)
Missing	18 (1.4)	0 (0.0)
Recent Antibiotic Treatment		
Yes	101 (8.0)	26 (8.3)
No	1124 (89.2)	286 (91.1)
Unknown/Missing	35 (2.8)	2 (0.6)
Recent Respiratory Infection		
Yes	365 (29.0)	61 (19.4)
No	860 (68.3)	250 (79.6)
Unknown/Missing	35 (2.8)	3 (1.0)
Vaccination Status		
Up-to-date	1022 (81.1)	270 (86.0)
Not up-to-date	40 (3.2)	10 (3.2)
Unknown/Missing	198 (15.7)	34 (10.8)
Costs per participant (£)		
Laboratory consumables	8.06	8.47
Printing	2.14	7.23
Swabs and swab packs	17.08	9.65
Service Support Costs (SSC)	2.81	39.52
Transport (by taxi or internal mail)	0.00	4.78
Postage	11.12	0.00
Total	41.21	69.66

Costs (Pounds Sterling) are per participant taking into account wastage of swabs and swab packs; HCP = Healthcare professional.

Table 2. Bacterial Nose and Nasopharyngeal Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *S. aureus*, *H. influenzae* and *P. aeruginosa* by Participant Age Group, Recent RTI, Recent Antibiotic Treatment and Vaccination Status

Carriage of Bacterial Species within Nose and Nasopharyngeal Swabs in different Participant Categories													
Category	Participants (N)		<i>S. pneumoniae</i>		<i>H. influenzae</i>		<i>M. catarrhalis</i>		<i>S. aureus</i>		<i>P. aeruginosa</i>		
	SS	HCP	Nose	NP	Nose	NP	Nose	NP	Nose	NP	Nose	NP	
Age (years)													
0-4	329	56	32.8(108) (27.7, 37.9)	33.9(19) (21.5, 46.3)	7.3(24) (4.5, 10.1)	10.7(6) (2.6, 18.8)	5.8(19) (3.3, 8.3)	10.7(6) (2.6, 18.8)	9.7(32) (6.5, 12.9)	5.4(3) (-0.5, 11.3)	2.7(9) (1.0, 4.5)	1.8(1) (-1.7, 5.3)	
5-17	137	22	13.1(18) (7.5, 18.8)	9.1(2) (-2.9, 21.1)	5.1(7) (1.4, 8.8)	0.0(0) N/A	0.7(1) (-0.7, 2.1)	4.5(1) (-4.1, 13.2)	35.0(48) (27.0, 43.0)	13.6(3) (-0.7, 27.9)	0.7(1) (-0.7, 2.1)	0.0(0) N/A	
18-64	464	88	1.1(5) (0.2, 2.1)	0.0(0) N/A	0.2(1) (-0.2, 0.6)	1.1(1) (-1.1, 3.3)	1.5(7) (0.4, 2.6)	3.4(3) (-0.4, 7.2)	24.8(115) (20.9, 28.7)	11.4(10) (4.8, 18.0)	1.3(6) (0.3, 2.3)	1.1(1) (-1.1, 3.3)	
65+	304	143	2.0(6) (0.4, 3.6)	1.4(2) (-0.5, 3.3)	0.7(2) (-0.2, 1.6)	0.0(0) N/A	1.3(4) (0.0, 2.6)	2.8(4) (0.1, 5.5)	23.2(71) (18.5, 27.9)	15.4(22) (9.5, 21.3)	1.0(3) (-0.1, 2.1)	1.4(2) (-0.5, 3.3)	
<i>p</i>			<0.001*	<0.001	<0.001	<0.001	0.001	0.100	<0.001*	0.263	0.288	1.000	
Recent Respiratory Tract Infection													
Yes	363	59	22.3(81) (18.0, 26.6)	15.3(9) (6.1, 24.5)	5.2(19) (2.9, 7.5)	6.8(4) (0.4, 13.2)	3.6(13) (1.7, 5.5)	3.4(2) (-1.2, 8.0)	19.3(70) (15.2, 23.4)	6.8(4) (0.4, 13.2)	2.2(8) (0.7, 3.7)	3.4(2) (-1.2, 8.0)	
No	856	247	6.3(54) (4.7, 7.9)	5.7(14) (2.8, 8.6)	1.6(14) (0.8, 2.4)	1.2(3) (-0.2, 2.6)	2.1(18) (1.1, 3.1)	4.9(12) (2.2, 7.6)	22.3(191) (19.5, 25.1)	13.8(34) (9.5, 18.1)	1.3(11) (0.5, 2.1)	0.8(2) (-0.3, 1.9)	
<i>p</i>			<0.001*	0.023	0.001*	0.028	0.163*	1.000	0.253*	0.188*	0.310*	0.169	
Recent use of Antibiotics													
Yes	101	26	5.9(6) (1.3, 10.5)	3.8(1) (-3.6, 11.2)	1.0(1) (-0.9, 2.9)	0.0(0) N/A	1.0(1) (-0.9, 2.9)	3.8(1) (-3.6, 11.2)	15.8(16) (8.7, 22.9)	0.0(0) N/A	1.0(1) (-0.9, 2.9)	7.7(2) (-2.6, 18.0)	
No	1118	281	11.5(129) (9.6, 13.4)	7.8(22) (4.7, 10.9)	2.9(32) (1.9, 3.9)	2.5(7) (0.7, 4.3)	2.7(30) (1.8, 3.7)	4.6(13) (2.2, 7.1)	21.7(243) (19.3, 24.1)	13.5(38) (9.5, 17.5)	1.5(17) (0.8, 2.2)	0.7(2) (-0.3, 1.7)	
<i>p</i>			0.097*	0.706	0.515	1.000	0.508	1.000	0.203*	0.056	1.000	0.037	
Vaccinations up-to-date													
Yes	1017	265	12.8(130) (10.8, 14.9)	8.7(23) (5.3, 12.1)	3.0(31) (2.0, 4.1)	2.6(7) (0.7, 4.5)	2.8(28) (1.8, 3.8)	4.5(12) (2.0, 7.0)	20.4(207) (17.9, 22.9)	13.2(35) (9.1, 17.3)	1.6(16) (0.8, 2.4)	1.5(4) (0.0, 3.0)	
No	40	10	5.0(2) (-1.8, 11.8)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	10.0(1) (-8.6, 28.6)	25.0(10) (11.6, 38.4)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A	
<i>p</i>			0.219	1.000	1.000	1.000	1.000	0.389	0.548*	0.621	0.484	1.000	

1
2
3
4 Chi-squared (indicated by *) and Fisher's exact tests for independence were used to determine significant differences between bacterial carriage rates in different age
5 groups, with/without recent RTI, with/without recent antibiotic treatment and with/without an up-to-date vaccination status. P-values are 2-tailed. 95% CI are written as
6
7 (upper CI, lower CI). NP = Nasopharyngeal swab. N/A = not applicable.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

Table 3. Bacterial Self-taken and HCP-taken Whole Mouth Swab Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *S. aureus*, *H. influenzae* and *P. aeruginosa* by Participant

Age Group, Recent RTI, Recent Antibiotic Treatment and Vaccination Status

Category	Participants (N)		Carriage of Bacterial Species within Mouth Swabs in different Participant Categories									
			% (n) (95% CI)									
			<i>S. pneumoniae</i>		<i>H. influenzae</i>		<i>M. catarrhalis</i>		<i>S. aureus</i>		<i>P. aeruginosa</i>	
SS	HCP	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	
Age (years)												
0-4	329	56	1.2(4) (0.0, 2.4)	3.6(2) (-1.3, 8.5)	1.2(4) (0.0, 2.4)	5.4(3) (-0.5, 11.3)	11.9(39) (8.4, 15.4)	37.5(21) (24.8, 50.2)	2.4(8) (0.8, 4.1)	0.0(0) N/A	4.9(16) (2.6, 7.2)	3.6(2) (-1.3, 8.5)
5-17	137	22	1.5(2) (-0.5, 3.5)	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	11.7(16) (6.3, 17.1)	31.8(7) (12.3, 51.3)	4.4(6) (1.0, 7.8)	4.5(1) (-4.2, 13.2)	3.6(5) (0.5, 6.7)	0.0(0) N/A
18-64	464	88	0.0(0) N/A	0.0(0) N/A	0.9(4) (0.0, 1.8)	1.1(1) (-1.1, 3.3)	15.9(74) (15.6, 19.2)	23.9(21) (15.0, 32.8)	3.0(14) (1.5, 4.6)	2.3(2) (-0.8, 5.4)	1.7(8) (0.5, 2.9)	2.3(2) (-0.8, 5.4)
65+	304	143	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	0.7(1) (-0.7, 2.1)	14.7(45) (10.7, 18.7)	32.2(46) (24.5, 39.9)	1.6(5) (0.2, 3.0)	1.4(2) (-0.5, 3.3)	2.9(9) (1.0, 4.8)	3.5(5) (0.5, 6.5)
<i>p</i>			0.006	0.063	0.204	0.159	0.330*	0.348*	0.361	0.377	0.079	0.910
Recent Respiratory Tract Infection												
Yes	363	59	0.8(3) (-0.1, 1.7)	1.7(1) (-1.6, 5.0)	0.8(3) (-0.1, 1.7)	1.7(1) (-1.6, 5.0)	11.0(40) (7.8, 14.2)	28.8(17) (17.3, 40.4)	2.5(9) (0.9, 4.1)	0.0(0) N/A	3.9(14) (1.9, 5.9)	5.1(3) (-0.5, 10.7)
No	856	247	0.4(3) (0.0-0.8)	0.4(1) (-0.4, 1.2)	0.6(5) (0.1, 1.1)	1.6(4) (0.0, 3.2)	15.4(132) (13.0, 17.8)	31.2(77) (25.4, 37.0)	2.7(23) (1.6, 3.8)	1.6(4) (0.0, 3.2)	2.8(24) (1.7, 3.9)	2.4(6) (0.5, 4.3)
<i>p</i>			0.370	0.349	0.701	1.000	0.048*	0.756*	0.850*	1.000	0.368*	0.382
Recent use of Antibiotics												
Yes	101	26	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	14.9(15) (8.0, 21.8)	26.9(7) (9.9, 43.9)	3.0(3) (-0.3, 6.3)	3.8(1) (-3.6, 11.2)	2.0(2) (-0.7, 4.7)	3.8(1) (-3.6, 11.2)
No	1118	281	0.5(6) (0.1, 0.9)	0.7(2) (-0.3, 1.7)	0.7(8) (0.2, 1.2)	1.8(5) (0.3, 3.4)	14.1(158) (12.1, 16.1)	31.0(87) (25.6, 36.4)	2.6(29) (1.7, 3.5)	1.4(4) (0.0, 2.8)	3.2(36) (2.2, 4.2)	2.8(8) (0.9, 4.7)
<i>p</i>			1.000	1.000	1.000	1.000	0.881*	0.825*	0.744	0.360	0.764	0.554
Vaccinations up-to-date												
Yes	1017	265	0.6(6) (0.1, 1.1)	0.8(2) (-0.3, 1.9)	0.6(6) (0.1, 1.1)	1.9(5) (0.3, 3.5)	14.3(145) (12.2, 16.5)	31.3(83) (25.7, 36.9)	2.8(28) (1.8, 3.8)	1.5(4) (0.0, 3.0)	3.2(33) (2.1, 4.3)	3.0(8) (1.0, 5.1)
No	40	10	0.0(0) N/A	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A	5.0(2) (-1.8, 11.8)	50.0(5) (19.0, 81.0)	2.5(1) (-2.3, 7.3)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A
<i>p</i>			1.000	1.000	0.237	1.000	0.106*	0.299	1.000	1.000	1.000	1.000

1
2
3
4
5
6 Chi-squared (indicated by *) and Fisher's exact tests for independence were used to determine significant differences between bacterial carriage rates in different age
7
8 groups, with/without recent RTI, with/without recent antibiotic treatment and with/without an up-to-date vaccination status. P-values are 2-tailed. 95% CI are written as
9
10 (upper CI, lower CI). WMS = whole mouth swab. N/A = not applicable.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49






For peer review only

Table 4. Differences in Bacterial Carriage Rate of *S. pneumoniae*, *M. catarrhalis*, *S. aureus*, *H. influenzae* and *P. aeruginosa* between Swab Types According to Age, Recent RTI, Recent Antibiotic Treatment and Vaccination Status

Category	Bacterial Species Carriage Differential between Swab Types									
	<i>S. pneumoniae</i>		<i>H. influenzae</i>		<i>M. catarrhalis</i>		<i>S. aureus</i>		<i>P. aeruginosa</i>	
	Nose – NP	SS WMS – HCP WMS	Nose – NP	SS WMS – HCP WMS	Nose – NP	SS WMS – HCP WMS	Nose – NP	SS WMS – HCP WMS	Nose – NP	SS WMS – HCP WMS
Age (years)										
0-4	-1.1 (-2.1, -0.1) 0.879*	-2.4 (-3.9, -0.9) 0.212	-3.4 (-5.2, -1.6) 0.416	-4.2 (-6.2, -2.2) 0.067	-4.9 (-7.1, -2.7) 0.234	-25.6 (-30.0, -21.2) <0.001	4.3 (2.3, 6.3) 0.333*	2.4 (0.9, 3.9) 0.609	0.9 (0.0, 1.8) 1.000	1.3 (0.2, 2.4) 1.000
5-17	4.0 (1.0, 7.0) 1.000	1.5 (-0.4, 3.4) 1.000	5.1 (1.7, 8.5) 0.594	0.0 N/A N/A	-3.8 (-6.8, -0.9) 0.258	-20.1 (-26.3, -13.9) 0.021	21.4 (15.0, 27.8) 0.051*	-0.1 (-0.6, 0.4) 1.000	0.7 (-0.6, 2.0) 1.000	3.6 (0.7, 6.5) 1.000
18-64	1.1 (0.2, 2.0) 1.000	0.0 N/A N/A	-0.9 (-1.7, -0.1) 0.294	-0.2 (-0.6, 0.2) 0.582	-1.9 (-3.0, -0.8) 0.203	-8.0 (-10.3, -5.7) 0.089*	13.4 (10.6, 16.2) 0.008*	0.7 (0.0, 1.4) 1.000	0.2 (-0.2, 0.6) 1.000	-0.6 (-1.2, 0.0) 0.665
65+	0.6 (-0.1, 1.3) 1.000	0.0 N/A N/A	0.7 (-0.1, 1.5) 1.000	-0.7 (-1.5, 0.1) 0.318	-1.5 (-2.6, -0.4) 0.272	-17.5 (-21.0, -14.0) <0.001	7.8 (5.3, 10.3) 0.061*	0.2 (-0.2, 0.6) 1.000	-0.4 (-1.0, 0.2) 0.656	-0.6 (-1.3, 0.1) 0.774
Recent Respiratory Tract Infection										
Yes	7.0 (4.6, 9.4) 0.237*	-0.9 (-1.8, 0.0) 0.454	-1.6 (-2.8, -0.4) 0.546	-0.9 (-1.8, 0.0) 0.454	0.2 (-0.2, 0.6) 1.000	-17.8 (-21.5, -14.2) 0.001*	12.5 (9.3, 15.7) 0.016*	2.5 (1.0, 4.0) 0.620	-1.2 (-2.2, -0.2) 0.637	-1.2 (-2.2, -0.2) 0.718
No	0.6 (0.2, 1.1) 0.766*	0.0 N/A N/A	0.4 (0.0, 0.8) 0.777	-1.0 (-1.6, -0.4) 0.120	-2.8 (-3.8, -1.8) 0.026*	-15.8 (-18.0, -13.7) <0.001*	8.5 (6.9, 10.1) 0.003*	1.1 (0.5, 1.7) 0.369*	0.5 (0.1, 0.9) 0.744	0.4 (0.0, 0.8) 0.829*
Recent use of Antibiotics										
Yes	2.1 (-0.4, 4.6) 1.000	0.0 N/A N/A	1.0 (-0.7, 2.7) 1.000	0.0 N/A N/A	-2.8 (-5.7, 0.1) 0.369	-12.0 (-17.7, -6.4) 0.176	15.8 (9.5, 22.1) 0.041	-0.8 (-2.4, 0.8) 1.000	-6.7 (-11.1, -2.4) 0.106	-1.8 (-4.1, 0.5) 0.500
No	3.7 (2.7, 4.7) 0.085*	-0.2 (-0.4, 0.0) 0.665	0.4 (0.1, 0.7) 0.842*	-1.1 (-1.7, -0.6) 0.153	-1.9 (-2.6, -1.2) 0.119*	-16.9 (-18.9, -14.9) <0.001*	8.2 (6.8, 9.6) 0.003*	1.2 (0.6, 1.8) 0.282*	0.8 (0.3, 1.3) 0.396	0.4 (0.1, 0.7) 0.850*
Vaccinations up-to-date										
Yes	4.1 (3.0, 5.2)	-0.2 (-0.4, 0.0)	0.4 (0.1, 0.8)	-1.3 (-1.9, -0.7)	-1.7 (-2.4, -1.0)	-17.0 (-19.1, -14.9)	7.2 (5.8, 8.6)	1.3 (0.7, 1.9)	0.1 (-0.1, 0.3)	0.2 (0.0, 0.4)

	0.071*	0.673	0.841*	0.056	0.163*	<0.001*	0.008*	0.280*	1.000	1.000*
	5.0	0.0	2.5	2.5	-7.5	-45.0	25.0	2.5	2.5	2.5
No	(-1.0, 11.0)	N/A	(-1.8, 6.8)	(-1.8, 6.8)	(-14.8, -0.2)	(-58.8, -31.2)	(13.0, 37.0)	(-1.8, 6.8)	(-1.8, 6.8)	(-1.8, 6.8)
	1.000	N/A	1.000	1.000	0.363	0.002	0.179	1.000	1.000	1.000

Chi-squared (indicated by *) and Fisher's exact tests for independence were used to determine significant differences between bacterial carriage rates in different swab types according to age, recent RTI, recent antibiotic treatment and vaccination status. P-values are 2-tailed. WMS = whole mouth swab, NP = Nasopharyngeal swab.




1
2
3 **Figure 1.** Bacterial Carriage Rates (%) of (A) *S. pneumoniae* (B) *M. catarrhalis* (C) *S. aureus* (D) *H. influenzae* (E) *P.*
4
5 *aeruginosa* by Swab Method and Site

6
7 Graphs are bar charts representing carriage frequencies as percentages. Error bars represent 95% Confidence Intervals.

8
9 Striped boxes represent nose swabs, white boxes represent self-taken WMS, dotted boxes represent NP swabs and
10
11 grey boxes represent HCP-taken WMS.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only

Supplementary File



Supplementary Figure 1. Total Positivity Rates of the Four Swab Types

Bar chart showing positivity rates for all four swab types. WMS = whole mouth swab, NP = nasopharyngeal swab. Error bars represent 95% confidence intervals. Numbers of positive swabs are shown above each bar.



Supplementary Figure 2. Total Bacterial Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *P. aeruginosa*, *S. aureus* and *H. influenzae* in all swab types by geographical location of practices

Pie charts represent total bacterial carriage rates (%) in each GP practice with size representing proportionate amounts of bacterial carriage. Percentages of each bacterium within the total carriage rate are represented by coloured sections within each pie chart. Red lines are major roads, blue lines are rivers and darker areas of land represent cities.

Supplementary Table 1. Microbiology Identification Techniques for the Six Target

Bacterial Species

Bacterial species	Identification Technique
<i>S. pneumoniae</i>	Characteristic gram-positive alpha-haemolytic optochin-sensitive colonies growing on blood agar with nalidixic acid.
<i>H. influenzae</i>	Characteristic small gram-negative colonies requiring X+V factors growing on chocolate blood agar with bacitracin.
<i>M. catarrhalis</i>	Characteristic gram-negative tributyrin test-positive diplococci growing on blood agar.
<i>P. aeruginosa</i>	Characteristic gram-negative oxidase-positive green colonies growing on <i>Pseudomonas</i> -selective CFC agar.
<i>S. aureus</i>	Characteristic gram-positive coagulase-positive colonies growing on blood agar.
<i>N. meningitidis</i>	Characteristic oxidase-positive gram-negative diplococci growing on <i>Neisseria</i> -selective GC agar and matching the correct API NH profile.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1 and 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7 and 8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	9
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7 and 11
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	22
		(b) Indicate number of participants with missing data for each variable of interest	22
Outcome data	15*	Report numbers of outcome events or summary measures	11 and 12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11 and 12
		(b) Report category boundaries when continuous variables were categorized	22
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13-14
Discussion			
Key results	18	Summarise key results with reference to study objectives	15-17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15-17
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Evaluation of swabbing methods for estimating the prevalence of bacterial carriage in the upper respiratory tract: a cross sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005341.R1
Article Type:	Research
Date Submitted by the Author:	28-Aug-2014
Complete List of Authors:	Coughtrie, Abigail; University of Southampton, Faculty of Medicine Whittaker, Robert; University of Southampton, Faculty of Medicine Begum, Nelupha; University of Southampton, Faculty of Medicine Anderson, Rebecca; University of Southampton, Faculty of Medicine Tuck, Andy; University of Southampton, Faculty of Medicine Faust, Saul; University of Southampton, Faculty of Medicine Jefferies, Johanna; University of Southampton, Faculty of Medicine Yuen, Ho Ming; University of Southampton, Faculty of Medicine Roderick, Paul; University of Southampton, Faculty of Medicine Mullee, Mark; University of Southampton, Faculty of Medicine Moore, Michael; University of Southampton, Faculty of Medicine Clarke, Stuart; University of Southampton, Faculty of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Respiratory medicine, Infectious diseases
Keywords:	Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES, MICROBIOLOGY, Respiratory infections < THORACIC MEDICINE, PRIMARY CARE

SCHOLARONE™
Manuscripts

1
2
3 Evaluation of swabbing methods for estimating the prevalence of
4
5
6 bacterial carriage in the upper respiratory tract: a cross sectional
7
8
9
10 study

11
12
13
14
15 A L Coughtrie¹, R N Whittaker¹, N Begum¹; R Anderson¹; A Tuck¹; S N Faust^{1,2,3}; J M Jefferies^{1,3}; H
16
17 M Yuen¹; P J Roderick¹; M A Mullee^{1,4}; M V Moore¹; S C Clarke^{1,3,5}
18
19

20
21
22
23 ¹Faculty of Medicine and Institute for Life Sciences, University of Southampton, UK; ²Southampton
24
25 NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton Foundation NHS
26
27 Trust, Southampton, UK; ³Southampton NIHR Respiratory Biomedical Research Unit, University
28
29 Hospital Southampton Foundation NHS Trust, Southampton, UK; ⁴NIHR Research Design Service
30
31 South Central, University Hospital Southampton Foundation NHS Trust, Southampton, UK; ⁵Public
32
33 Health England, Southampton, UK;
34
35

36
37
38 Correspondence to:

39
40 Dr Stuart C. Clarke

41
42 Infectious Disease Epidemiology Group, University of Southampton, Mailpoint 814, Level C, South
43
44 Block, University Hospital Southampton Foundation NHS Trust, Southampton SO16 6YD, UK

45
46 S.C.Clarke@southampton.ac.uk
47
48

49
50 Running Title:

51
52 Swabbing methods for the estimation of respiratory bacterial carriage
53
54
55
56
57
58
59
60

Abstract

Objectives. Bacterial carriage in the upper respiratory tract is usually asymptomatic but can lead to respiratory tract infection (RTI), meningitis and septicaemia. We aimed to provide a baseline measure of *Streptococcus pneumoniae*, *Moraxella catarrhalis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Haemophilus influenzae* and *Neisseria meningitidis* carriage within the community. Self-swabbing and healthcare professional (HCP) swabbing, via nasopharyngeal (NPS) and WMS, was compared.

Design. Cross-sectional study.

Setting. Individuals registered at 20 general practitioner (GP) practices within the Wessex Primary Care Research Network South West, United Kingdom.

Participants. 10,448 individuals were invited to participate; 5,394 within a self-swabbing group and 5,054 within a HCP swabbing group. Self-swabbing invitees included 2,405 individuals aged 0-4 years and 3,349 individuals aged ≥ 5 years. HCP swabbing invitees included 1,908 individuals aged 0-4 years and 3,146 individuals aged ≥ 5 years.

Results. 1,574 (15.1%) individuals participated, 1,260 (23.4%, 95% CI 22.3%–24.5%) undertaking self-swabbing and 314 (6.2%, 95% CI 5.5%–6.9%) undertaking HCP-led swabbing. Participation was lower in young children and more deprived practice locations. Swab positivity rates were 34.8% (95% CI 32.2%–37.4%) for NS, 19.0% (95% CI 16.8%–21.2%) for self-taken WMS, 25.2% (95% CI 20.4%–30.0%) for NPS and 33.4% (95% CI 28.2%–38.6%) for HCP-taken WMS. Carriage rates of *S. aureus* were highest in NS (21.3%). *S. pneumoniae* carriage was highest in NS (11.0%) and NPS (7.4%). *M. catarrhalis* carriage was highest in HCP-taken WMS (28.8%). *H. influenzae* and *P. aeruginosa* carriage were similar between swab types. *N. meningitidis* was not detected in any swab. Age and recent RTI affected carriage of *S. pneumoniae* and *H. influenzae*. Participant costs were lower for self-swabbing (£41.21) versus HCP swabbing (£69.66).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions. Higher participation and lower costs of self-swabbing as well as sensitivity of self-swabbing favour this method for use in large population-based respiratory carriage studies.

For peer review only

Strengths and limitations of this study

- This study is the largest community-based swabbing study to date to compare carriage rates of multiple bacterial species simultaneously between self-swabbing and healthcare professional swabbing methods.
- This study provides important evidence for the use of nose swabs for detection of *Streptococcus pneumoniae* and other respiratory pathogens.
- Non-response bias needs to be considered within both self-swabbing and HCP swabbing groups.

1 INTRODUCTION

2 The respiratory tract is host to a wide variety of commensal and pathogenic microorganisms, with
3 approximately 250 species colonising the nasopharynx alone (1). Asymptomatic carriage in the upper
4 respiratory tract (URT) is the first stage in the process of RTI, meningitis and sepsis. Carriage often
5 occurs without disease but may also lead to serious invasive illness (2, 3). In 2010, approximately 4.4
6 million deaths worldwide resulted from an RTI, most commonly in young children (4).

7 Collecting samples from the URT enables the estimation of carriage rates of pathogenic organisms.
8 The determination of carriage rates is essential for assessing circulating respiratory microbes which
9 may go on to cause disease. A number of sites within the URT have been used to assess carriage,
10 including the nasopharynx, oropharynx, nose and throat. Methods for assessing carriage have
11 included swabbing, nose blowing and nasopharyngeal aspiration (5-12). However, no single study
12 has evaluated the use of different swabbing methods using a large population-based sample. *S.*
13 *pneumoniae* remains the only bacterial species for which a WHO standard method has been
14 established for detecting carriage (13). It is currently recommended to take a nasopharyngeal swab
15 despite other sites being equally as effective, if not more sensitive, in assessing carriage of this
16 organism (7, 10). Self-swabbing has also been shown to be effective in assessing nasal carriage of *S.*
17 *aureus* and viruses and offers a cheaper alternative to more traditional healthcare professional (HCP)
18 swabbing (12, 14).

19 Most carriage studies have focused on a particular organism and participant age group. However,
20 many microorganisms are thought to play a role in RTI development and carriage in all age groups is
21 important in terms of understanding disease transmission and immunity against specific pathogens
22 (15). Moreover, in the current vaccine era, we are likely to see an explosion of new vaccines during
23 the coming decade that will affect the respiratory tract microbiota (16-20). This highlights the need
24 for large population-based studies that include all age groups and aim to detect as many relevant
25 microbial species as possible.

1
2
3 26 Our study aimed to provide a baseline measure for understanding multi-species bacterial carriage in
4
5 27 the respiratory tract within the general population of one geographical area of the UK. The
6
7 28 objectives were to assess the optimal sample collection method and site by comparing self-taken
8
9 29 nose and mouth swabs with HCP-taken nasopharyngeal and mouth swabs; to gain an estimate of
10
11 30 participant consent rates in both study groups and to test the feasibility of conducting a larger multi-
12
13 31 site investigation. Finally, the study aimed to estimate carriage rates of relevant URT bacterial
14
15 32 species. This would help inform samples sizes for multi-centre studies, particularly for use in pre-
16
17 33 and post-vaccine studies, as well as to aid in understanding the effects of demographic factors and
18
19 34 deprivation on carriage.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 35 **METHODS**
4
5 36
6
7 37 **Sample Size**
8
9
10 38 This was a pilot study and not designed to have the power to detect non-inferiority of estimating
11 39 carriage rates by HCP-administered versus self-administered swabs. Data from this study was
12 40 predicted to inform sample sizes required for future large carriage studies. The sample size for this
13 41 pilot study was based on the precision with which we can estimate true carriage rates. A 25%
14 42 response rate among self-swabbing participants was assumed based on results from a previous
15 43 staphylococcal carriage study (12). A 25% response rate was also assumed for HCP-swabbing.
16
17
18 44 We estimated that by inviting 2,020 children (101 from each GP practice) aged 0-4 years and 3,200
19 45 older children and adults (160 from each GP practice) to participate within each swabbing group, this
20 46 would result in 505 children and 800 older children and adult responders within each swabbing
21 47 group, accounting for predicted lower carriage rates in older children and adults. A predicted
22 48 carriage rate of 30% in 505 participating children would enable the determination of true carriage to
23 49 within $\pm 4.0\%$ (95% confidence) (21). A predicted carriage rate of 20% in 800 participating older
24 50 children and adults would enable the determination of true carriage to within $\pm 2.8\%$ (95%
25 51 confidence) (9).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 52
45
46
47 53 **Participant Recruitment**
48
49
50 54 Participants were selected from twenty general practitioner (GP) practices within the Wessex
51 55 Primary Care Research Network (PCRN) South West (East hub) area, in Southern England. GP
52 56 practices were chosen to reflect a mix of urban/rural locations, practice sizes and area deprivation
53 57 levels. Each GP practice produced a list of their entire patient cohort. Any individual deemed unfit
54 58 for participation at the discretion of their GP, for example due to terminal illness or serious mental
55
56
57
58
59
60

1
2
3 59 health problems, was removed from the list. From each GP list, 202 individuals aged 0-4 years and
4
5 60 320 individuals aged ≥ 5 years were randomly selected and allocated to one of two study groups
6
7 61 using the *ralloc* command in Stata 12. This resulted in approximately 101 individuals aged 0-4 years
8
9 62 and 160 individuals aged ≥ 5 years within each swabbing group per GP practice.

10
11
12 63 The HCP group involved participants being invited, via letter, to organise a swabbing appointment at
13
14 64 their GP practice where nasopharyngeal (NPS) and whole mouth (WMS) swabs were taken by a
15
16 65 registered HCP. Appointments were within normal surgery opening hours and at the individuals' GP
17
18 66 practice (local to each participant). The self-swabbing group involved participants being sent a self-
19
20 67 swabbing pack containing nose (NS) and whole mouth (WMS) swabs by Danvers International
21
22 68 (London, UK). Participants were not sent reminders. All swab heads were viscose (rayon). Nose and
23
24 69 both whole mouth swab shafts were polystyrene whereas NP swab shafts were aluminium. Once
25
26 70 taken, swabs were placed in polypropylene tubes containing amies transport medium with charcoal.
27
28 71 HCP-taken swabs were returned for analysis on the day of swabbing by taxi or within 1-2 days by
29
30 72 pre-existing NHS delivery service. Self-taken swabs were returned by first-class freepost return (1-2
31
32 73 days).

33
34
35
36
37 74 Each participant was given an age-appropriate information sheet explaining the study aims, which
38
39 75 aimed to motivate individuals to participate. Participants were asked to complete a consent form
40
41 76 and questionnaire, provided either at their swabbing appointment or within their self-swabbing
42
43 77 pack. The study questionnaire was identical for both study groups and requested the following
44
45 78 details pertinent to bacterial carriage: participant age, recent use of antibiotics (within the past
46
47 79 month), recent RTI (cold, flu, ear infection or chest infection within the past month) and vaccination
48
49 80 status. Age was split into the following groups for analysis: 0-4 years, 5-17 years, 18-64 years and 65
50
51 81 years and older due to the relevance of each of these age groups in carriage of the different bacterial
52
53 82 species. Recent use of antibiotics and recent RTI were split into the following groups for analysis:
54
55 83 yes, no and do not know/missing. Vaccination status was split into the following groups for analysis:
56
57
58
59
60

1
2
3 84 up-to-date, not up-to-date and do not know/missing. UK Index of Multiple Deprivation (IMD) 2010
4
5 85 scores were obtained for each GP practice based on the Lower layer Super Output Area (LSOA) it
6
7 86 was located in and was used as a proxy for deprivation of each practices' patient population (22). UK
8
9 87 IMD 2010 Score includes seven features of deprivation: income, education, employment, health,
10
11 88 housing, crime and living environment. More deprived areas have lower levels of these seven
12
13 89 features where as less deprived areas have higher levels for the same seven features. This would
14
15 90 enable the relationship between carriage and deprivation to be assessed, as in disease studies (23).
16
17 91 A total of 10,448 individuals were invited to participate in the study.
18
19
20
21 92
22
23
24 93 **Sample Collection and Analysis**
25
26
27 94 Self-swabbing packs were sent out to individuals between the 15th May and 23rd July 2012 and
28
29 95 samples were received between the 18th May and 31st August 2012. HCP swabbing appointments
30
31 96 took place between 7th June and 28th August and samples were received between the 7th June and
32
33 97 31st August. Upon receipt, swabs were immersed in skim milk, tryptone, glucose and glycerine
34
35 98 (STGG) storage media, vigorously rubbed against the side of the tube and vortexed to ensure
36
37 99 transfer of bacteria into the STGG. Standard microbiology culture and identification techniques were
38
39 100 used to analyse the swab contents for the presence of *Streptococcus pneumoniae*, *Haemophilus*
40
41 101 *influenzae*, *Moraxella catarrhalis*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Neisseria*
42
43 102 *meningitidis*. This was done by transferring 10µl STGG onto Columbia blood agar with horse blood
44
45 103 (Oxoid, PB0124), Columbia blood agar with colistin and nalidixic acid (Oxoid, PB0308), Columbia
46
47 104 blood agar with chocolated horse blood (Oxoid, PB0124), Columbia blood agar with chocolated
48
49 105 horse blood and bacitracin (Oxoid, PB0220), *Pseudomonas* selective agar (Oxoid, PB0291) and lysed
50
51 106 GC selective agar (Oxoid, PB0962). Identification of each bacterial species was undertaken according
52
53 107 to methodology described in Supplementary Table 1. After plating, the remaining swab content in
54
55 108 STGG was then frozen for future use at -70°C.
56
57
58
59
60

1
2
3 1094
5 110 **Statistical Analysis**6
7 111 Culture data and participant questionnaire information were tabulated into SPSS (v20) for analysis.8
9 112 Missing or incomplete data was classed as missing within the SPSS variables window. Participation10
11 113 rates, the proportion of participants relative to total number of individuals invited, were calculated12
13 114 for each GP practice and age group. UK IMD 2010 scores for each GP practice area were examined in14
15 115 relation to participation rates using Pearson's Correlation. Swab positivity rates, the proportion of16
17 116 swabs that isolated any of the target bacteria relative to total swab numbers, were calculated for18
19 117 each swab type. Confidence Intervals (95% CI) were calculated to assess reliability of participation20
21 118 and positivity rates.22
23 119 Carriage rates, the proportion of a specific bacterial species relative to total number of swabs, were24
25 120 calculated according to swab type, age, recent RTI, recent antibiotic use, vaccination status,26
27 121 geographical location and deprivation. Chi-squared and Fisher's Exact tests were used to determine28
29 122 any associations between carriage and these variables. Geographical mapping of carriage rates was30
31 123 performed using ArcGIS (ESRI, v10.1) (24). Practices were grouped into geographical areas for32
33 124 statistical analysis based on proximity to one another. Finally, co-carriage rates, the proportion of34
35 125 samples containing multiple bacterial species relative to total number of swabs, were calculated36
37 126 according to swab type, age, recent RTI, recent antibiotic use, vaccination status and geographical38
39 127 location.40
41 12842
43 129 **Study Costs**44
45 130 Total costs associated with each swabbing method were calculated to allow cost comparisons46
47 131 between methods. Costs were calculated as total costs within a single swabbing group divided by the48
49 132 total number of responders from that swabbing group. This included swab packs sent out to50
51 133 individuals but not used. Costs were separated into laboratory consumables, printing, swabs,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

134 National Health Service (NHS) Service Support Costs (additional healthcare costs due to the research
135 taking place), transport and postage.

For peer review only

RESULTS**Participation Rates**

Eighteen of the 20 GP practices participated in both self- and HCP-swabbing, one participated in self-swabbing only and one dropped out of the study. Participant characteristics are shown in table 1. Overall participation rates were higher in the self-swabbing group at 23.4% ($n=1,260$; $N=5,395$; 95% CI 22.3%–24.5%) compared with the HCP group at 6.2% ($n=314$; $N=5,054$; 95% CI 5.5%–6.9%). Self-swabbing participation rates varied from 9.3% ($n=27$; $N=290$) to 33.1% ($n=96$; $N=290$) between practices whereas HCP participation rates varied from 1.0% ($n=3$; $N=290$) to 12.3% ($n=34$; $N=277$). Ten practices had participation rates $\geq 25\%$ in the self-swabbing group, which was the anticipated level of participation. There was a negative correlation between participation rate and IMD score in the self-swabbing group ($r=-0.473$, $p=0.041$) and the HCP group ($r=-0.417$, $p=0.085$), which was only significant in the former. Participation was higher in individuals aged ≥ 5 years at 27.8% ($n=931$; $N=3,349$; 95% CI 26.8%–29.3%) in the self-swabbing group and 8.2% ($n=258$; $N=3,146$; 95% CI 7.2%–9.2%) in the HCP group versus 0-4 years at 16.1% ($n=329$; $N=2,045$; 95% CI 14.5%–17.7%) in the self-swabbing group and 2.9% ($n=56$; $N=1,908$; 95% CI 2.2%–3.7%) in the HCP group. The greatest number of responses received was from individuals aged 50-80 years, comprising 41.7% ($n=656$, $N=1,574$) of total participants.

153

Swab Positivity Rates

Out of 1,260 self-swabbing participants, 1,254 returned both swabs with labels distinguishing nose from WMS but six individuals failed to label their swabs and thus were excluded from analyses. Out of 314 HCP swabbing participants, 309 had both swabs returned by their GP but five individuals were incorrectly swabbed by their GP and thus were excluded from analyses. Swab positivity rates were 35.0% ($n=439$; $N=1,254$; 95% CI 32.4%–37.6%) for NS, 19.1% ($n=239$; $N=1,254$; 95% CI 16.9%–21.3%) for self-taken WMS, 25.6% ($n=79$; $N=309$; 95% CI 20.7%–30.5%) for NPS and 34.0% ($n=105$; $N=309$;

1
2
3 161 95% CI 28.7%–39.3%) for HCP-taken WMS (Supplementary Figure 1). The nose swab (NS) and HCP-
4
5 162 taken WMS were most effective in detecting carriage of the target organisms. Positivity rates of NS
6
7 163 were significantly higher than NPS ($\chi^2=9.974$, $df=1$, $p=0.002$). Positivity rates of HCP-taken WMS
8
9 164 were significantly higher than self-taken WMS ($\chi^2=32.157$, $df=1$, $p<0.001$).
10
11

165

166 **Bacterial Carriage Rates**

167 Carriage rates within each swab type (Figure 1) show few significant differences between self-
18
19 168 swabbing and HCP swabbing. *S. pneumoniae* carriage was similar between NS and NPS ($\chi^2=3.403$,
20
21 169 $df=1$, $p=0.075$) and between self-taken and HCP-taken WMS (test value=0.139, $df=1$, $p=0.661$). *M.*
22
23 170 *catarrhalis* carriage was similar between NS and NPS ($\chi^2=3.757$, $df=1$, $p=0.058$) but significantly
24
25 171 higher in HCP-taken WMS compared to self-taken WMS ($\chi^2=43.404$, $df=1$, $p<0.001$). *S. aureus*
26
27 172 carriage was significantly higher in NS than NPS ($\chi^2=13.161$, $df=1$, $p<0.001$) but was similarly low in
28
29 173 self-taken and HCP-taken WMS ($\chi^2=1.218$, $df=1$, $p=0.315$). *H. influenzae* carriage was similarly low in
30
31 174 NS and NPS ($\chi^2=0.193$, $df=1$, $p=0.700$) as well as in self-taken and HCP-taken WMS (test value=2.888,
32
33 175 $df=1$, $p=0.151$). *P. aeruginosa* carriage was similar in NS and NPS (test value=0.148, $df=1$, $p=1.000$) as
34
35 176 well as in self-taken and HCP-taken WMS ($\chi^2=0.032$, $df=1$, $p=1.000$). *N. meningitidis* was not detected
36
37 177 in any swab type used in this study.
38
39
40
41

178

179 **Co-carriage Rates**

180 Overall co-carriage rates were 3.9% ($n=49$; $N=1,219$; 95% CI 2.8%–5.0%) in NS, 1.1% ($n=13$; $N=1,219$;
46
47 181 95% CI 0.5%–1.7%) in self-taken WMS, 2.3% ($n=7$; $N=307$; 95% CI 0.6%–4.0%) in NPS and 1.6% ($n=5$;
48
49 182 $N=307$; 95% CI 0.2%–3.0%) in HCP-taken WMS. In NS and NPS, co-carriage rates were significantly
50
51 183 higher in individuals aged 0-4 years (NS [9.1%; $n=30$; $N=329$; 95% CI 6.0%–12.2%] and NPS [8.9%;
52
53 184 $n=5$; $N=56$, 95% CI 1.4%–16.4%]) versus ≥ 5 years (NS [2.1%; $n=19$; $N=907$; 95% CI 1.2%–3.0%] and
54
55 185 NPS [1.8%; $n=2$; $N=253$, 95% CI 0.2%–3.4%]). Nose co-colonisation decreased with age, with 8.0%
56
57
58
59
60

1
2
3 186 ($n=11$; $N=137$, 95% CI 3.5%–12.5%) in individuals aged 5-17 years, 1.1% ($n=5$; $N=464$; 95% CI 0.2%–
4
5 187 2.1%) in individuals aged 18-64 years and 1.0% ($n=3$; $N=306$; 95% CI -0.1%–2.1%) in those aged ≥ 65
6
7 188 years. The most common co-colonisation relationship in nose swabs was between *S. pneumoniae*
8
9 189 and *H. influenzae* (50% [$n=15$; $N=30$] in 0-5 years, 26.3% [$n=5$, $N=19$] in ≥ 5 years).
10
11
12
13

190

191 **Association between Demographics and Carriage**

192 *Participant age*

193 Bacterial carriage was highly variable with age, in particular carriage of *S. pneumoniae*, *H. influenzae*
194 *M. catarrhalis* and *S. aureus* (Tables 2-3). Carriage rates of *S. pneumoniae* and *H. influenzae* in both
195 NS and NPS decreased with age, with 0-4 year olds experiencing the highest carriage rates. *S.*
196 *pneumoniae* carriage dropped off significantly after 5 years of age with $>2x$ difference in NS and $>3x$
197 difference in NPS between those aged 0-4 years and those aged 5-17 years. *S. pneumoniae* carriage
198 in self-taken WMS also showed higher carriage in the young (0-4 years and 5-17 years age groups)
199 compared with adults. *H. influenzae* nasal carriage decreased more steadily with age. *M. catarrhalis*
200 nose carriage was also highest in those aged 0-4 years but remained at lower levels in the other age
201 groups. *S. aureus* nose carriage increased sharply after the age of 5 years but remained high in older
202 children and adults. *S. aureus* nose carriage was $>3x$ higher in participants aged 5-17 years when
203 compared with participants 0-4 years. *P. aeruginosa* did not vary between the age groups in any
204 swab type.
205
206
207

207 *Participant questionnaire information*

208 Higher nasal and NP carriage rates of *S. pneumoniae* and *H. influenzae* were observed in participants
209 who had experienced a recent RTI. *S. pneumoniae* nose carriage was $>3x$ higher in those with recent
210 RTI versus those without recent RTI, using the Fisher's Exact test ($X^2=66.408$, $df=1$, $p<0.001$). *H.*

1
2
3 211 *influenzae* nose carriage was also >2x higher in those with recent RTI versus those without recent
4
5 212 RTI, using the Chi-squared test ($\chi^2=12.533$, $df=1$, $p=0.001$). Recent antibiotic treatment was only
6
7 213 significant in *P. aeruginosa* NP carriage, where recent antibiotics use was associated with increased
8
9 214 carriage of this bacterium (test value=9.018, $df=1$, $p=0.037$). Vaccination status was not associated
10
11 215 with significant changes in carriage of any of the target bacteria. Full results are shown in Tables 2
12
13 216 and 3. In NS, recent RTI was also associated with higher co-carriage rates at 8.0% ($n=29$) when
14
15 217 compared with no recent RTI at 2.2% ($n=19$). Recent antibiotic use, vaccination status and
16
17 218 geographical location did not appear to affect co-carriage rates.

219 *Geographical location*

220 Carriage rates of the target bacterial species showed some differences according to practice location
221 (Supplementary Figure 2). Overall bacterial carriage was significantly different by geographical area
222 in NS ($\chi^2=11.609$, $df=5$, $p=0.04$) and self-taken WMS ($\chi^2=13.900$, $df=5$, $p=0.02$) but not in either HCP
223 swab. However, individual bacteria carriage rates were not significantly different between
224 geographical areas.

225 *Deprivation*

226 Participants attending practices in less deprived locations had slightly higher bacterial carriage rates,
227 except for *P. aeruginosa*, suggesting a possible negative relationship between deprivation score and
228 bacterial carriage. However the differences observed were not statistically significant.

229

230

231 **Study Costs**

232 Overall, total costs per participant were over a third lower in the self-swabbing group at £41.21
233 (\$67.92) versus the HCP group at £69.66 (\$114.82) (Table 1). NHS service support costs made up a
234 large proportion of the difference between the two study groups, representing 56.7%

1
2
3 235 (£39.52/person) of costs in the HCP group but only 6.8% (£2.81/person) of costs in the self-swabbing
4
5 236 group.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

237 **DISCUSSION**

238 Our study demonstrates that self-swabbing is as effective in detecting bacterial pathogens in the
239 respiratory tract as HCP swabbing and that nose swabs could be used more routinely to detect the
240 presence of bacterial pathogens *S. pneumoniae*, *H. influenzae*, *S. aureus* and *P. aeruginosa*. Whole
241 mouth swabs, on the other hand, are the most sensitive swab for detection of *M. catarrhalis*. The
242 swabs used in this study were not sensitive for detection of *N. meningitidis*.

243 Higher participation rates within the self-swabbing group compared with the HCP group highlight
244 the willingness of individuals to participate in such studies when the process is facilitated. The very
245 low participation rate of the HCP group would render this method invalid for large-scale studies.
246 Whilst the responsiveness of the self-swabbing group was higher, it was still less than the
247 anticipated 25%, meaning there will always be a problem of non-response bias. However, similar
248 carriage rates were observed in our study when compared with previous swabbing studies,
249 demonstrating that our sample size is large enough to overcome differences that may result from
250 non-response bias. Barriers to participation in the HCP group might include the amount of time
251 required for organising and attending swabbing appointments and the slight discomfort experienced
252 during nasopharyngeal swabbing. Self-swabbing overcame many of these barriers by offering a
253 relatively straightforward, rapid and easy alternative. High participation rates in elderly participants
254 might be a result of their increased availability for participation and their increased chance of
255 exposure to RTI allowing them to relate to the study aims. Parents may also be reluctant to swab
256 their children if they are very young. The negative correlation between participation rates and
257 deprivation highlights certain barriers associated with high levels of deprivation, which have been
258 observed in other studies (25).

259 Swab positivity rates and bacterial carriage rates indicate that self-swabbing is as effective as HCP
260 swabbing in sampling microbial species within the airways of the general population within our large
261 population-based study. Higher positivity rates in NS versus NPS and higher carriage of *S. aureus*

1
2
3 262 within NS versus NPS demonstrate the potential for using a self-taken NS rather than HCP-taken NPS
4
5 263 to detect respiratory pathogens. Higher positivity rates in HCP-taken WMS versus self-taken WMS
6
7 264 and higher carriage of *M. catarrhalis* within HCP-taken WMS demonstrate the sensitivity of HCP-
8
9 265 swabbing. However, lower participation rates with fewer children and more elderly participants
10
11 266 within HCP swabbing have most probably resulted in reduced carriage rates within NPS. Self-
12
13 267 swabbing allowed the recruitment of a greater spread of age groups, which is essential for obtaining
14
15 268 a true estimate of carriage. Very low participation in the HCP group is problematic for assessing
16
17 269 carriage within the general population as fewer numbers of samples can be obtained and the cost of
18
19 270 obtaining them is high. In order to obtain the same spread of ages as the self-swabbing group, a
20
21 271 much larger number of individuals would need to be invited. The high costs of HCP swabbing are
22
23 272 mainly due to the operation of swabbing clinics. In order to increase participation, healthcare
24
25 273 providers could undertake verbal encouragement or study advertisement in practice. WMS were
26
27 274 efficient in isolating *M. catarrhalis* and *P. aeruginosa*, however, large amounts of background flora
28
29 275 within this site and low isolation levels for the other bacteria render this swab less efficient on the
30
31 276 whole. The lack of isolation of *N. meningitidis* may be due to the type of swabs used, as
32
33 277 oropharyngeal swabs are often preferred (26). Low response rates from teenagers, the most
34
35 278 frequent carriers of *N. meningitidis*, may also have caused the lack of isolation of this species (27).
36
37
38
39
40 279 Carriage rates of five out of the six target organisms follow previously observed patterns with *S.*
41
42 280 *pneumoniae* and *H. influenzae* being carried predominantly in young children and *S. aureus* being
43
44 281 carried more in older children and adults (12, 28, 29). *M. catarrhalis* and *P. aeruginosa* carriage rates
45
46 282 were constant across all age groups demonstrating that carriage of these organisms is unaffected by
47
48 283 age. *N. meningitidis* carriage did not follow previously observed patterns as no isolates were
49
50 284 detected. However, the number of participants in the study may not have been large enough to
51
52 285 detect any isolates with 95% confidence. Furthermore, swab types used and turn-around times from
53
54 286 swabbing to sample processing may not be optimal for *N. meningitidis* recovery. The effect of recent
55
56 287 RTI on carriage of *S. pneumoniae* and *H. influenzae* is one that might be expected as colds and flu
57
58
59
60

1
2
3 288 weaken host immunity allowing for carriage by these organisms (30). The lack of an apparent effect
4
5 289 of vaccination status is potentially due to herd immunity, as unvaccinated people benefit from
6
7 290 protection from disease as a result of a largely vaccinated population (31). However, further details
8
9 291 of vaccines received via access to individual participant immunisation records in future studies might
10
11 292 enable improved assessment of the effects of immunisation on carriage of target and non-target
12
13
14 293 bacteria.

15
16
17 294 This pilot study has also enabled all aspects of study set-up through to completion to be tried and
18
19 295 tested, which will be essential for setting up larger swabbing studies. Study documentation, study
20
21 296 protocol, ethics application and sample size calculations have been trialled and alterations can now
22
23 297 be preformed on further studies in order to improve outcomes and efficiency. Limitations, including
24
25 298 numbers of non-responses, can be improved in further studies in order to increase confidence in
26
27 299 study outcomes. The results from this pilot study have allowed the comparison of swabbing
28
29 300 methodologies for determining carriage of the targeted bacterial species within the respiratory tract.
30
31 301 The advantages of self-swabbing are evident with higher responsiveness and lower costs than HCP
32
33 302 swabbing. Further assessment will determine whether our findings are applicable to other
34
35 303 geographical locations, over time and to a wider array of bacterial species. Such assessment would
36
37 304 help to refine methodologies, which will be key to obtaining a precise understanding of bacterial
38
39 305 carriage in the respiratory tract.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding

This work was supported by the Rosetrees Trust [M141 to S.C.C.] and the Bupa Foundation [TBF-M11-019 to S.C.C.].

Conflicts of Interest

S.N.F. receives support from the National Institute for Health Research funding via the Southampton NIHR Wellcome Trust Clinical Research Facility and the Southampton NIHR Respiratory Biomedical Research Unit. J.M.J. has received consulting fees from GlaxoSmithKline. S.N.F. acts as principal investigator for clinical trials conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receives no personal payments from them. S.N.F. has participated in advisory boards for vaccine manufacturers but receives no personal payments for this work. S.C.C. currently receives unrestricted research funding from Pfizer Vaccines (previously Wyeth Vaccines) and has participated in advisory boards and expert panels for GSK, Pfizer and Novartis. S.C.C. is an investigator on studies conducted on behalf of University Hospital Southampton NHS Foundation Trust / University of Southampton / Public Health England that are sponsored by vaccine manufacturers but receives no personal payments from them. S.N.F., S.C.C. and J.M.J. have received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. All other authors have no conflicts of interest.

Author Contributions and Acknowledgments

ALC: Study set-up, data collection, data analysis and writing; RNW: Study set-up, data collection, proof-reading of manuscript; NB: Data collection, proof-reading of manuscript; RA: Data collection, proof-reading of manuscript; AT: Study design, data collection, proof-reading of manuscript; SNF: Study design, data analysis, proof-reading of manuscript; JMJ: Study design, data analysis, proof-

1
2
3 reading of manuscript; HMY: Study design, data analysis, proof-reading of manuscript; PJR: Study
4
5 design, data analysis, proof-reading of manuscript; MAM: Study design, data analysis, proof-reading
6
7 of manuscript; MVM: Study design, data analysis, proof-reading of manuscript; SCC: Study design,
8
9 data collection, data analysis, proof-reading of manuscript.
10

11
12 We thank Shabana Hussain and Karen Cox for technical assistance throughout the study. We also
13
14 thank the Bupa Foundation for providing the funding to SCC in order to undertake the study and the
15
16 Rosetrees Trust for their funding contribution for ALC's PhD studentship. We thank the
17
18 Southampton NIHR Wellcome Trust Clinical Research Facility for part-funding SNF. We also thank the
19
20 National Institute for Health Research Comprehensive Local Research Network (NIHR CLRN), NHS
21
22 Service Support Costs, Solent Primary Care Trust (PCT), South West (East Hub) Primary Care
23
24 Research Network (PCRN) and Danvers International for their contributions.
25
26
27

28 **Data Sharing Statement:**

29
30
31 No additional data available
32
33

34 **Figure Legends**

35
36
37 **Figure 1.** Bacterial Carriage Rates (%) of (A) *S. pneumoniae* (B) *M. catarrhalis* (C) *S. aureus* (D) *H. influenzae* (E)
38
39 *P. aeruginosa* by Swab Method and Site
40
41

42 Graphs are bar charts representing carriage frequencies as percentages. Error bars represent 95% Confidence
43
44 Intervals.
45

46 **Supplementary Figure 1.** Total Positivity Rates of the Four Swab Types

47
48
49 Bar chart showing positivity rates for all four swab types. WMS = whole mouth swab, NP =
50
51 nasopharyngeal swab. Error bars represent 95% confidence intervals. Numbers of positive swabs are
52
53 shown above each bar.
54
55
56
57
58
59
60

1
2
3 **Supplementary Figure 2.** Total Bacterial Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *P.*

4 *aeruginosa*, *S. aureus* and *H. influenzae* in all swab types by geographical location of practices

5
6
7
8 Pie charts represent total bacterial carriage rates (%) in each GP practice with size representing
9
10 proportionate amounts of bacterial carriage. Percentages of each bacterium within the total carriage
11
12 rate are represented by coloured sections within each pie chart. Red lines are major roads, blue lines
13
14 are rivers and darker areas of land represent cities.

15
16
17 **Supplementary Table 1.** Microbiology Identification Techniques for the Six Target Bacterial Species

References

1. Bogaert D, Keijser B, Huse S, *et al.* Variability and diversity of nasopharyngeal microbiota in children: a metagenomic analysis. *PLoS One* 2011;6:e17035.
2. Faden H, Duffy L, Wasielewski R, *et al.* Relationship between Nasopharyngeal Colonization and the Development of Otitis Media in Children. *J Infect Dis* 1997;175:1440-5.
3. Brueggemann AB, Griffiths DT, Meats E, *et al.* Clonal relationships between invasive and carriage *Streptococcus pneumoniae* and serotype- and clone-specific differences in invasive disease potential. *J Infect Dis* 2003;187:1424-32.
4. Lozano R, Naghavi M, Foreman K, *et al.* Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2095-128.
5. Akmatov MK, Krebs S, Preusse M, *et al.* E-mail-based symptomatic surveillance combined with self-collection of nasal swabs: a new tool for acute respiratory infection epidemiology. *Int J Infect Dis* 2011;15:e799-803.
6. Leach AJ, Stubbs E, Hare K, *et al.* Comparison of nasal swabs with nose blowing for community-based pneumococcal surveillance of healthy children. *Journal of clinical microbiology*. 2008;46(6):2081-2.
7. Lieberman D, Shleyfer E, Castel H, *et al.* Nasopharyngeal versus oropharyngeal sampling for isolation of potential respiratory pathogens in adults. *J Clin Microbiol* 2006;44:525-8.
8. Trotter CL, Gay NJ. Analysis of longitudinal bacterial carriage studies accounting for sensitivity of swabbing: an application to *Neisseria meningitidis*. *Epidemiol Infect* 2003;130(2):201-5.
9. Watt JP, O'Brien KL, Katz S, *et al.* Nasopharyngeal versus oropharyngeal sampling for detection of pneumococcal carriage in adults. *J Clin Microbiol* 2004;42:4974-6.
10. Rapola S, Salo E, Kiiski P, *et al.* Comparison of Four Different Sampling Methods for Detecting Pharyngeal Carriage of *Streptococcus pneumoniae* and *Haemophilus influenzae* in Children. *J Clin Microbiol* 1997;35:1077-9.
11. Greenberg D, Broides A, Blancovich I, *et al.* Relative importance of nasopharyngeal versus oropharyngeal sampling for isolation of *Streptococcus pneumoniae* and *Haemophilus influenzae* from healthy and sick individuals varies with age. *J Clin Microbiol* 2004;42:4604-9.
12. Gamblin J, Jefferies JM, Harris S, *et al.* Nasal self-swabbing for estimating the prevalence of *Staphylococcus aureus* in the community. *J Med Microbiol* 2013;62:437-40.
13. Satzke C, Turner P, Virolainen-Julkunen A, *et al.* Standard method for detecting upper respiratory carriage of *Streptococcus pneumoniae*: Updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. *Vaccine* 2013;32:165-79.
14. Akmatov MK, Gatzemeier A, Schughart K, *et al.* Equivalence of self- and staff-collected nasal swabs for the detection of viral respiratory pathogens. *PLoS One* 2012;7:e48508.
15. de Roux A, Ewig S, Garcia E, *et al.* Mixed community-acquired pneumonia in hospitalised patients. *Eur Respir J* 2006;27:795-800.
16. Harro CD, Betts RF, Hartzel JS, *et al.* The immunogenicity and safety of different formulations of a novel *Staphylococcus aureus* vaccine (V710): results of two Phase I studies. *Vaccine* 2012;30:1729-36.
17. Moore R, Kyd JM, Carzino R, *et al.* Mucosal and systemic antibody responses to potential *Pseudomonas aeruginosa* vaccine protein antigens in young children with cystic fibrosis following colonization and infection. *Hum Vaccin Immunother* 2012;9:506-14.
18. Serruto D, Bottomley MJ, Ram S, *et al.* The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. *Vaccine* 2012;30:B87-97.
19. Sheldon E, Schwartz H, Jiang Q, *et al.* A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. *Hum Vaccin Immunother* 2012;8:888-95.

- 1
2
3 20. Skinner JM, Indrawati L, Cannon J, *et al*. Pre-clinical evaluation of a 15-valent pneumococcal
4 conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. *Vaccine*
5 2011;29:8870-6.
6
7 21. Tocheva AS, Jefferies JM, Rubery H, *et al*. Declining serotype coverage of new pneumococcal
8 conjugate vaccines relating to the carriage of *Streptococcus pneumoniae* in young children. *Vaccine*
9 2011;29:4400-4.
10 22. UK Department for Communities and Local Government. English indices of deprivation 2010
11 [Document on the Internet]. London: Department for Communities and Local Government; 2011
12 [cited 2014 Aug 22]. Available from: [https://www.gov.uk/government/publications/english-indices-](https://www.gov.uk/government/publications/english-indices-of-deprivation-2010)
13 [of-deprivation-2010](https://www.gov.uk/government/publications/english-indices-of-deprivation-2010).
14 23. Chapman KE, Wilson D, Gorton R. Invasive pneumococcal disease and socioeconomic
15 deprivation: a population study from the North East of England. *J Public Health* 2013;35:558-69.
16 24. ESRI. ArcGIS 10.1. Redlands, California: ESRI; 2012.
17 25. Sheron N, Moore M, O'Brien W, *et al*. Feasibility of detection and intervention for alcohol-
18 related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS). *Br J*
19 *Gen Pract* 2013;63:e698-705.
20 26. Olcen P, Kjellander J, Danielsson D, *et al*. Culture diagnosis of meningococcal carriers: yield
21 from different sites and influence of storage in transport medium. *J Clin Pathol* 1979;32:1222-5.
22 27. Cartwright KA, Stuart JM, Jones DM, *et al*. The Stonehouse survey: nasopharyngeal carriage
23 of meningococci and *Neisseria lactamica*. *Epidemiol Infect* 1987;99:591-601.
24 28. Gray BM, Converse GM, Dillon HC. Epidemiologic studies of *Streptococcus pneumoniae* in
25 infants: acquisition, carriage, and infection during the first 24 months of life. *J Infect Dis*
26 1980;142:923-33.
27 29. Peltola H, Kilpi T, Anttila M. Rapid disappearance of *Haemophilus influenzae* type b
28 meningitis after routine childhood immunisation with conjugate vaccines. *Lancet* 1992;340:592-4.
29 30. Brundage JF. Interactions between influenza and bacterial respiratory pathogens:
30 implications for pandemic preparedness. *Lancet Infect Dis* 2006;6:303-12.
31 31. Ramsay ME, Andrews NJ, Trotter CL, *et al*. Herd immunity from meningococcal serogroup C
32 conjugate vaccination in England: database analysis. *BMJ* 2003;326:365-6.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Participant Characteristics and Study Costs (in British Pounds) for Self-swabbing and HCP swabbing

Participant characteristics n(%) and costs per participant (£)		
	Self-swabbing	HCP swabbing
Age (years)		
Mean	37.42	50.09
Minimum	0	0
Maximum	94	88
0-4	329 (26.1)	56 (17.8)
5-17	137 (10.9)	24 (7.6)
18-64	465 (36.9)	89 (28.3)
65+	311 (24.7)	145 (46.2)
Missing	18 (1.4)	0 (0.0)
Recent Antibiotic Treatment		
Yes	101 (8.0)	26 (8.3)
No	1124 (89.2)	286 (91.1)
Unknown/Missing	35 (2.8)	2 (0.6)
Recent Respiratory Infection		
Yes	365 (29.0)	61 (19.4)
No	860 (68.3)	250 (79.6)
Unknown/Missing	35 (2.8)	3 (1.0)
Vaccination Status		
Up-to-date	1022 (81.1)	270 (86.0)
Not up-to-date	40 (3.2)	10 (3.2)
Unknown/Missing	198 (15.7)	34 (10.8)
Costs per participant (£)		
Laboratory consumables	8.06	8.47
Printing	2.14	7.23
Swabs and swab packs	17.08	9.65
Service Support Costs (SSC)	2.81	39.52
Transport (by taxi or internal mail)	0.00	4.78
Postage	11.12	0.00
Total	41.21	69.66

Costs (British Pounds) are per participant taking into account wastage of swabs and swab packs; HCP = Healthcare professional.

Table 2. Bacterial Nose and Nasopharyngeal Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *S. aureus*, *H. influenzae* and *P. aeruginosa* by Participant Age Group, Recent RTI, Recent Antibiotic Treatment and Vaccination Status

Carriage of Bacterial Species within Nose and Nasopharyngeal Swabs in different Participant Categories													
Category	Participants (N)		<i>S. pneumoniae</i>		<i>H. influenzae</i>		<i>M. catarrhalis</i>		<i>S. aureus</i>		<i>P. aeruginosa</i>		
	SS	HCP	Nose	NP	Nose	NP	Nose	NP	Nose	NP	Nose	NP	
Age (years)													
0-4	329	56	32.8(108) (27.7, 37.9)	33.9(19) (21.5, 46.3)	7.3(24) (4.5, 10.1)	10.7(6) (2.6, 18.8)	5.8(19) (3.3, 8.3)	10.7(6) (2.6, 18.8)	9.7(32) (6.5, 12.9)	5.4(3) (-0.5, 11.3)	2.7(9) (1.0, 4.5)	1.8(1) (-1.7, 5.3)	
5-17	137	22	13.1(18) (7.5, 18.8)	9.1(2) (-2.9, 21.1)	5.1(7) (1.4, 8.8)	0.0(0) N/A	0.7(1) (-0.7, 2.1)	4.5(1) (-4.1, 13.2)	35.0(48) (27.0, 43.0)	13.6(3) (-0.7, 27.9)	0.7(1) (-0.7, 2.1)	0.0(0) N/A	
18-64	464	88	1.1(5) (0.2, 2.1)	0.0(0) N/A	0.2(1) (-0.2, 0.6)	1.1(1) (-1.1, 3.3)	1.5(7) (0.4, 2.6)	3.4(3) (-0.4, 7.2)	24.8(115) (20.9, 28.7)	11.4(10) (4.8, 18.0)	1.3(6) (0.3, 2.3)	1.1(1) (-1.1, 3.3)	
65+	306	143	2.0(6) (0.4, 3.6)	1.4(2) (-0.5, 3.3)	0.7(2) (-0.2, 1.6)	0.0(0) N/A	1.3(4) (0.0, 2.6)	2.8(4) (0.1, 5.5)	23.2(71) (18.5, 27.9)	15.4(22) (9.5, 21.3)	1.0(3) (-0.1, 2.1)	1.4(2) (-0.5, 3.3)	
<i>p</i>			<0.001*	<0.001	<0.001	<0.001	0.001	0.100	<0.001*	0.263	0.288	1.000	
Recent Respiratory Tract Infection													
Yes	363	59	22.3(81) (18.0, 26.6)	15.3(9) (6.1, 24.5)	5.2(19) (2.9, 7.5)	6.8(4) (0.4, 13.2)	3.6(13) (1.7, 5.5)	3.4(2) (-1.2, 8.0)	19.3(70) (15.2, 23.4)	6.8(4) (0.4, 13.2)	2.2(8) (0.7, 3.7)	3.4(2) (-1.2, 8.0)	
No	856	247	6.3(54) (4.7, 7.9)	5.7(14) (2.8, 8.6)	1.6(14) (0.8, 2.4)	1.2(3) (-0.2, 2.6)	2.1(18) (1.1, 3.1)	4.9(12) (2.2, 7.6)	22.3(191) (19.5, 25.1)	13.8(34) (9.5, 18.1)	1.3(11) (0.5, 2.1)	0.8(2) (-0.3, 1.9)	
<i>p</i>			<0.001*	0.023	0.001*	0.028	0.163*	1.000	0.253*	0.188*	0.310*	0.169	
Recent use of Antibiotics													
Yes	101	26	5.9(6) (1.3, 10.5)	3.8(1) (-3.6, 11.2)	1.0(1) (-0.9, 2.9)	0.0(0) N/A	1.0(1) (-0.9, 2.9)	3.8(1) (-3.6, 11.2)	15.8(16) (8.7, 22.9)	0.0(0) N/A	1.0(1) (-0.9, 2.9)	7.7(2) (-2.6, 18.0)	
No	1118	281	11.5(129) (9.6, 13.4)	7.8(22) (4.7, 10.9)	2.9(32) (1.9, 3.9)	2.5(7) (0.7, 4.3)	2.7(30) (1.8, 3.7)	4.6(13) (2.2, 7.1)	21.7(243) (19.3, 24.1)	13.5(38) (9.5, 17.5)	1.5(17) (0.8, 2.2)	0.7(2) (-0.3, 1.7)	
<i>p</i>			0.097*	0.706	0.515	1.000	0.508	1.000	0.203*	0.056	1.000	0.037	
Vaccinations up-to-date													
Yes	1017	265	12.8(130) (10.8, 14.9)	8.7(23) (5.3, 12.1)	3.0(31) (2.0, 4.1)	2.6(7) (0.7, 4.5)	2.8(28) (1.8, 3.8)	4.5(12) (2.0, 7.0)	20.4(207) (17.9, 22.9)	13.2(35) (9.1, 17.3)	1.6(16) (0.8, 2.4)	1.5(4) (0.0, 3.0)	
No	40	10	5.0(2) (-1.8, 11.8)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	10.0(1) (-8.6, 28.6)	25.0(10) (11.6, 38.4)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A	
<i>p</i>			0.219	1.000	1.000	1.000	1.000	0.389	0.548*	0.621	0.484	1.000	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Chi-squared (indicated by *) and Fisher’s exact tests for independence were used to determine significant differences between bacterial carriage rates in different age groups, with/without recent RTI, with/without recent antibiotic treatment and with/without an up-to-date vaccination status. P-values are 2-tailed, significant values are highlighted in bold. 95% CI are written as (upper CI, lower CI). NP = Nasopharyngeal swab. N/A = not applicable.

For peer review only

Table 3. Bacterial Self-taken and HCP-taken Whole Mouth Swab Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *S. aureus*, *H. influenzae* and *P. aeruginosa* by Participant

Age Group, Recent RTI, Recent Antibiotic Treatment and Vaccination Status

Category	Participants (N)		Carriage of Bacterial Species within Mouth Swabs in different Participant Categories									
	SS	HCP	<i>S. pneumoniae</i>		<i>H. influenzae</i>		<i>M. catarrhalis</i>		<i>S. aureus</i>		<i>P. aeruginosa</i>	
			Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS
% (n) (95% CI)												
Age (years)												
0-4	329	56	1.2(4) (0.0, 2.4)	3.6(2) (-1.3, 8.5)	1.2(4) (0.0, 2.4)	5.4(3) (-0.5, 11.3)	11.9(39) (8.4, 15.4)	35.7(20) (23.2, 48.3)	2.4(8) (0.8, 4.1)	0.0(0) N/A	4.9(16) (2.6, 7.2)	3.6(2) (-1.3, 8.5)
5-17	137	22	1.5(2) (-0.5, 3.5)	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	11.7(16) (6.3, 17.1)	27.3(6) (8.7, 45.9)	4.4(6) (1.0, 7.8)	4.5(1) (-4.2, 13.2)	3.6(5) (0.5, 6.7)	0.0(0) N/A
18-64	464	88	0.0(0) N/A	0.0(0) N/A	0.9(4) (0.0, 1.8)	1.1(1) (-1.1, 3.3)	15.3(71) (12.0, 18.6)	22.7(20) (14.0, 31.5)	3.0(14) (1.5, 4.6)	2.3(2) (-0.8, 5.4)	1.7(8) (0.5, 2.9)	2.3(2) (-0.8, 5.4)
65+	306	143	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	0.7(1) (-0.7, 2.1)	13.1(40) (9.3, 16.9)	30.1(43) (22.6, 37.6)	1.6(5) (0.2, 3.0)	1.4(2) (-0.5, 3.3)	2.9(9) (1.0, 4.8)	3.5(5) (0.5, 6.5)
<i>p</i>			0.006	0.063	0.204	0.159	0.476*	0.390*	0.361	0.377	0.079	0.910
Recent Respiratory Tract Infection												
Yes	363	59	0.8(3) (-0.1, 1.7)	1.7(1) (-1.6, 5.0)	0.8(3) (-0.1, 1.7)	1.7(1) (-1.6, 5.0)	10.5(38) (7.4, 13.7)	25.4(15) (14.3, 36.5)	2.5(9) (0.9, 4.1)	0.0(0) N/A	3.9(14) (1.9, 5.9)	5.1(3) (-0.5, 10.7)
No	856	247	0.4(3) (0.0-0.8)	0.4(1) (-0.4, 1.2)	0.6(5) (0.1, 1.1)	1.6(4) (0.0, 3.2)	14.7(126) (12.3, 17.1)	29.6(73) (23.9, 35.3)	2.7(23) (1.6, 3.8)	1.6(4) (0.0, 3.2)	2.8(24) (1.7, 3.9)	2.4(6) (0.5, 4.3)
<i>p</i>			0.370	0.349	0.701	1.000	0.054*	0.632*	0.850*	1.000	0.368*	0.382
Recent use of Antibiotics												
Yes	101	26	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	14.9(15) (8.0, 21.8)	23.1(6) (6.9, 39.3)	3.0(3) (-0.3, 6.3)	3.8(1) (-3.6, 11.2)	2.0(2) (-0.7, 4.7)	3.8(1) (-3.6, 11.2)
No	1118	281	0.5(6) (0.1, 0.9)	0.7(2) (-0.3, 1.7)	0.7(8) (0.2, 1.2)	1.8(5) (0.3, 3.4)	13.4(150) (11.4, 15.4)	29.2(82) (23.9, 34.5)	2.6(29) (1.7, 3.5)	1.4(4) (0.0, 2.8)	3.2(36) (2.2, 4.2)	2.8(8) (0.9, 4.7)
<i>p</i>			1.000	1.000	1.000	1.000	0.761*	0.652*	0.744	0.360	0.764	0.554
Vaccinations up-to-date												
Yes	1017	265	0.6(6) (0.1, 1.1)	0.8(2) (-0.3, 1.9)	0.6(6) (0.1, 1.1)	1.9(5) (0.3, 3.5)	13.7(139) (11.6, 15.8)	29.4(78) (23.9, 34.9)	2.8(28) (1.8, 3.8)	1.5(4) (0.0, 3.0)	3.2(33) (2.1, 4.3)	3.0(8) (1.0, 5.1)
No	40	10	0.0(0) N/A	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A	5.0(2) (-1.8, 11.8)	50.0(5) (19.0, 81.0)	2.5(1) (-2.3, 7.3)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A
<i>p</i>			1.000	1.000	0.237	1.000	0.153*	0.175	1.000	1.000	1.000	1.000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Chi-squared (indicated by *) and Fisher’s exact tests for independence were used to determine significant differences between bacterial carriage rates in different age groups, with/without recent RTI, with/without recent antibiotic treatment and with/without an up-to-date vaccination status. P-values are 2-tailed, significant values are highlighted in bold. 95% CI are written as (upper CI, lower CI). WMS = whole mouth swab. N/A = not applicable

For peer review only

1
2
3
4
5
6
7 Evaluation of swabbing methods for estimating the prevalence of
8
9
10 bacterial carriage in the upper respiratory tract: a cross sectional
11
12 study
13

14
15
16
17 A L Coughtrie¹, R N Whittaker¹, N Begum¹; R Anderson¹; A Tuck¹; S N Faust^{1,2,3}; J M Jefferies^{1,3}; H
18
19 M Yuen¹; P J Roderick¹; M A Mullee^{1,4}; M V Moore¹; S C Clarke^{1,3,5}
20
21

22
23
24 ¹Faculty of Medicine and Institute for Life Sciences, University of Southampton, UK; ²Southampton
25
26 NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton Foundation NHS
27
28 Trust, Southampton, UK; ³Southampton NIHR Respiratory Biomedical Research Unit, University
29
30 Hospital Southampton Foundation NHS Trust, Southampton, UK; ⁴NIHR Research Design Service
31
32 South Central, University Hospital Southampton Foundation NHS Trust, Southampton, UK; ⁵Public
33
34 Health England, Southampton, UK;
35

36
37 Correspondence to:

38
39 Dr Stuart C. Clarke

40
41 Infectious Disease Epidemiology Group, University of Southampton, Mailpoint 814, Level C, South
42
43 Block, University Hospital Southampton Foundation NHS Trust, Southampton SO16 6YD, UK
44

45
46 S.C.Clarke@southampton.ac.uk
47

48
49 Running Title:

50
51 Swabbing methods for the estimation of respiratory bacterial carriage
52
53
54
55

Abstract

Objectives. Bacterial carriage in the upper respiratory tract ~~is usually asymptomatic but can~~ leads to respiratory tract infection (RTI), meningitis and septicaemia. We aimed to provide a baseline measure of *Streptococcus pneumoniae*, *Moraxella catarrhalis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Haemophilus influenzae* and *Neisseria meningitidis* carriage within the community. Self-swabbing, ~~via nose (NS) and whole mouth swabs (WMS), and H~~healthcare professional (HCP) swabbing, via nasopharyngeal (NPS) and WMS, ~~was~~ere compared.

Design. Cross-sectional study.

Setting. ~~Patients-Individuals~~ registered at 20 general practitioner (GP) practices within the Wessex Primary Care Research Network South ~~WestEast hub~~, United Kingdom.

Participants. 10,448 ~~patients-individuals~~ were ~~invited to participate; 5,394 within a self-swabbing group and 5,054 within a HCP swabbing group. Self-swabbing invitees included 2,405 individuals aged 0-4 years and 3,349 individuals aged ≥5 years. HCP swabbing invitees included 1,908 individuals aged 0-4 years and 3,146 individuals aged ≥5 years. randomly selected to undertake either self-swabbing or HCP swabbing; 202 young children and 320 older children and adults from each GP practice. Patients deemed unfit for participation by their GP were excluded.~~

Results. 1,574 (15.1%) ~~patients-individuals~~ participated, 1,260 (23.4%, 95% CI 22.3%–24.5%) undertaking self-swabbing and 314 (6.2%, 95% CI 5.5%–6.9%) undertaking HCP-led swabbing. Participation was lower in young children and ~~in~~ more deprived practice locations. Swab positivity rates were 34.8% (95% CI 32.2%–37.45%) for NS, 19.06% (95% CI 16.87.4%–21.28%) for self-taken WMS, 25.27.4% (95% CI 20.42.5%-30.02.3%) for NPS and 33.44.1% (95% CI 28.28%-389.63%) for HCP-taken WMS. Carriage rates of *S. aureus* were highest in NS (21.3%). *S. pneumoniae* carriage was highest in NS (11.0%) and NPS (7.43%). *M. catarrhalis* carriage was highest in HCP-taken WMS (30.328.8%). *H. influenzae* and *P. aeruginosa* carriage were similar between swab types. *N.*

1
2
3
4
5
6
7 *meningitidis* was not detected in any swab. Age and recent RTI affected carriage of *S. pneumoniae*
8 and *H. influenzae*. Participant costs were lower for self-swabbing (£41.21) versus HCP swabbing
9 (£69.66).
10

11
12
13 **Conclusions.** Higher participation and lower costs of self-swabbing ~~and as well as higher~~
14 ~~sensitivity~~sensitivity of ~~nose self-swabbing swabs~~ favour this method for use in ~~future~~, large
15
16 population-based respiratory carriage studies.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This study is the largest community-based swabbing study to date to ~~report~~ compare carriage rates of multiple bacterial species simultaneously between self-swabbing and healthcare professional swabbing methods.
- This study provides important evidence for the use of nose swabs for detection of *Streptococcus pneumoniae* and other respiratory pathogens.
- Non-response bias needs to be considered within both self-swabbing and HCP swabbing groups.

INTRODUCTION

The respiratory tract is host to a wide variety of commensal and pathogenic microorganisms, with approximately 250 species colonising the nasopharynx alone [1]. Asymptomatic carriage in the upper respiratory tract (URT) is the first stage in the process of RTI, meningitis and sepsis. Carriage often occurs without disease but may also lead to serious invasive illness [2, 3]. In 2010, approximately 4.4 million deaths worldwide resulted from an RTI, most commonly in young children [4].

Collecting samples from the URT enables the estimation of carriage rates of pathogenic organisms. The determination of carriage rates is essential for assessing circulating respiratory microbes which may go on to cause disease. A number of sites within the URT have been used to assess carriage, including the nasopharynx, oropharynx, nose and throat. Methods for assessing carriage have included swabbing, nose blowing and nasopharyngeal aspiration [5-12]. However, no single study has evaluated the use of different swabbing methods using a large population-based sample. *S. pneumoniae* remains the only bacterial species for which a WHO standard method has been established for detecting carriage [13]. It is currently recommended to take a nasopharyngeal swab despite ~~the~~ other sites being equally as effective, if not more sensitive, in assessing carriage of this organism [7, 10]. Self-swabbing has also been shown to be effective in assessing nasal carriage of *S. aureus* and viruses and offers a cheaper alternative to more traditional healthcare professional (HCP) swabbing [12, 14].

Most carriage studies have focused on a particular organism and participant age group. However, many microorganisms are thought to play a role in RTI development and carriage in all age groups is important in terms of understanding disease transmission and immunity against specific pathogens [15]. Moreover, in the current vaccine era, we are likely to see an explosion of new vaccines during the coming decade that will affect the respiratory tract microbiota [16-20]. This highlights the need for large population-based studies ~~which that~~ include all age groups and aim to detect as many relevant microbial species as possible.

Formatted: Numbering: Continuous

1
2
3
4
5
6
7 26 Our study aimed to provide a baseline measure for understanding multi-species bacterial carriage in
8
9 27 the respiratory tract within the general population of one geographical area of the UK. The
10
11 28 objectives were to assess the optimal sample collection method and site by comparing self-taken
12
13 29 nose and mouth swabs with HCP-taken nasopharyngeal and mouth swabs; to gain an estimate of
14
15 30 participant consent rates in both study groups and to test the feasibility of conducting a larger multi-
16
17 31 site investigation. Finally, the study aimed to estimate carriage rates of relevant URT bacterial
18
19 32 species. This would help inform samples sizes for multi-centre studies, particularly for use in pre-
20
21 33 and post-vaccine studies, as well as to aid in understanding the effects of demographic factors and
22
23 34 deprivation on carriage.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 35 **METHODS**

8
9
10 37 **Sample Size**

11
12 38 This was a pilot study and not designed to have the power to detect non-inferiority of estimating
13
14 39 carriage rates by HCP-administered versus self-administered swabs. Data from this study was
15
16 40 predicted to inform sample sizes required for future large carriage studies. The sample size for this
17
18 41 pilot study was based on the precision with which we can estimate true carriage rates. A 25%
19
20 42 response rate among self-swabbing participants was assumed based on results from a previous
21
22 43 staphylococcal carriage study [12]. A 25% response rate was also assumed for HCP-swabbing.

23
24 44 ~~We estimated that by~~We invited 2,020 children ~~(101 from each GP practice)~~ aged 0-4 years and
25
26 45 3,200 older children and adults ~~(160 from each GP practice)~~ to participate ~~within each swabbing~~
27
28 46 ~~group, -anticipatthis would result in~~ 505 children and 800 older children ~~and /~~adult responders
29
30 47 ~~within each swabbing group,~~ accounting for predicted lower carriage rates in older children and
31
32 48 adults. A predicted carriage rate of 30% in 505 participating children would enable the
33
34 49 determination of true carriage to within $\pm 4.0\%$ (95% confidence) [21]. A predicted carriage rate of 20%
35
36 50 in 800 participating older children and adults would enable the determination of true carriage to
37
38 51 within $\pm 2.8\%$ (95% confidence) [9].

39
40 52
41
42 53 **Participant Recruitment**

43
44
45 54 Participants were selected from twenty general practitioner (GP) practices within the Wessex
46
47 55 Primary Care Research Network (PCRN) South ~~WestEast~~ ~~(East hub)~~ area, in Southern England. GP
48
49 56 practices were chosen to reflect a mix of urban/rural locations, practice sizes and area deprivation
50
51 57 levels. Each GP practice produced a list of their entire patient cohort. Any ~~patient-individual~~ deemed
52
53 58 unfit for participation ~~at the discretion of~~by their GP, for example due to terminal illness or serious

1
2
3
4
5
6
7 59 mental health problems, was removed from the list. From each GP list, 202 ~~patients~~individuals aged
8
9 60 0-4 years and 320 ~~patients~~individuals aged ≥ 5 years were randomly selected and allocated to one of
10
11 61 two study groups using the *ralloc* command in Stata 12. This resulted in approximately 101
12
13 62 individuals aged 0-4 years and 160 individuals aged ≥ 5 years within each swabbing group per GP
14
15 63 practice.

16
17 64 The HCP group involved participants being invited, via letter, to organise a swabbing appointment at
18
19 65 their GP practice where nasopharyngeal (NPS) and whole mouth (WMS) swabs were taken by a
20
21 66 registered HCP. Appointments were within normal surgery opening hours and at the individuals' GP
22
23 67 practice (local to each participant). The self-swabbing group involved participants being sent a self-
24
25 68 swabbing pack containing nose (NS) and whole mouth (WMS) swabs by Danvers International
26
27 69 (London, UK). Participants were not sent reminders. All swab heads were viscose (rayon). Nose and
28
29 70 both whole mouth swab shafts were polystyrene whereas NP swab shafts were aluminium. Once
30
31 71 taken, swabs were placed in polypropylene tubes containing amies transport medium with charcoal.
32
33 72 HCP-taken swabs were returned for analysis on the day of swabbing by taxi or within 1-2 days by
34
35 73 pre-existing NHS delivery service. Self-taken swabs were returned by first-class freepost return (1-2
36
37 74 days). WMS were used as a proxy for throat swabs, as the latter are difficult and uncomfortable to
38
39 75 self-perform.

40
41 76 Each participant was given an age-appropriate information sheet explaining the study aims, which
42
43 77 aimed to motivate individuals to participate. Participants were asked to complete a consent form
44
45 78 and questionnaire, provided either at their swabbing appointment or within their self-swabbing pack.
46
47 79 The study questionnaire was identical for both study groups and requested the following details
48
49 80 pertinent to bacterial carriage: participant age, recent use of antibiotics (within the past month),
50
51 81 recent RTI (cold, flu, ear infection or chest infection within the past month) and vaccination status.
52
53 82 Age was split into the following groups for analysis: 0-4 years, 5-17 years, 18-64 years and 65 years
54
55 83 and older due to the relevance of each of these age groups in carriage of the different bacterial

1
2
3
4
5
6
7 84 species. Recent use of antibiotics and recent [RTI](#) were split into the following groups for analysis: yes,
8
9 85 no and do not know/missing. Vaccination status was split into the following groups for analysis: up-
10
11 86 to-date, not up-to-date and do not know/missing. UK Index of Multiple Deprivation (IMD) 2010
12
13 87 scores were obtained for each GP practice based on the Lower layer Super Output Area (LSOA) it
14
15 88 was located in and was used as a proxy for deprivation of each practices' patient population [22]. [UK](#)
16
17 89 [IMD 2010 Score includes seven features of deprivation: income, education, employment, health,](#)
18
19 90 [housing, crime and living environment. More deprived areas have lower levels of these seven](#)
20
21 91 [features where as less deprived areas have higher levels for the same seven features.](#) This would
22
23 92 enable the relationship between carriage and deprivation to be assessed, as in disease studies [23].
24
25 93 A total of 10,448 ~~individuals patients~~ were invited to participate in the study, ~~approximately 526~~
26
27 94 ~~patients/practice.~~

95 96 **Sample Collection and Analysis**

97 [Self-swabbing packs were sent out to individuals between the 15th May and 23rd July 2012 and](#)
98 [samples were received between the 18th May and 31st August 2012](#) ~~Participants were invited to~~
99 [undertake swabbing between May-August 2012. HCP swabbing appointments took place between](#)
100 [7th June and 28th August and samples were received between the 7th June and 31st August. Swabs](#)
101 [were returned either via first class freepost return \(self-swabbing group\) or pre-existing NHS delivery](#)
102 [service or taxi \(HCP group\).](#) Upon receipt, swabs were immersed in skim milk, tryptone, glucose and
103 glycerine (STGG) storage media, vigorously rubbed against the side of the tube and vortexed to
104 ensure transfer of bacteria into the STGG. Standard microbiology culture and identification
105 techniques were used to analyse the swab contents for the presence of ~~*Streptococcus-*~~ *pneumoniae*,
106 ~~*Haemophilus-*~~ *influenzae*, ~~*Moraxella-*~~ *catarrhalis*, ~~*Staphylococcus-*~~ *aureus*, ~~*Pseudomonas-*~~ *aeruginosa*
107 and ~~*Neisseria-*~~ *meningitidis*. [This was done by transferring 10µl STGG onto Columbia blood agar with](#)
108 [horse blood \(Oxoid, PB0124\), Columbia blood agar with colistin and nalidixic acid \(Oxoid, PB0308\),](#)

1
2
3
4
5
6
7 109 Columbia blood agar with chocolated horse blood (Oxoid, PB0124), Columbia blood agar with
8 chocolated horse blood and bacitracin (Oxoid, PB0220), Pseudomonas selective agar (Oxoid, PB0291)
9 and lysed GC selective agar (Oxoid, PB0962). Identification of each bacterial species was undertaken
10 according to methodology described in Supplementary Table 1. After plating, the remaining swab
11 content in STGG was) before being then frozen for future use at -70°C.
12
13
14
15
16
17 114

18 115 **Statistical Analysis**

19
20 116 Culture data and participant questionnaire information were tabulated into SPSS (v20) for analysis.
21
22 117 Missing or incomplete data was classed as missing within the SPSS variables window. Participation
23
24 118 rates, the proportion of participants relative to total number of ~~individuals~~ patients invited, were
25
26 119 calculated for each GP practice and age group. UK IMD 2010 scores for each GP practice area were
27
28 120 examined in relation to participation rates using Pearson's Correlation. Swab positivity rates, the
29
30 121 proportion of swabs that isolated any of the target bacteria relative to total swab numbers, were
31
32 122 calculated for each swab type. Confidence Intervals (95% CI) were calculated to assess reliability of
33
34 123 participation and positivity rates.

35
36 124 Carriage rates, the proportion of a specific bacterial species relative to total number of swabs, were
37
38 125 calculated according to swab type, age, recent RTI, recent antibiotic use, vaccination status,
39
40 126 geographical location and deprivation. Chi-squared and Fisher's Exact tests were used to determine
41
42 127 any associations between carriage and these variables. Geographical mapping of carriage rates was
43
44 128 performed using ArcGIS (ESRI, v10.1) [24]. Practices were grouped into geographical areas for
45
46 129 statistical analysis based on proximity to one another. Finally, co-carriage rates, the proportion of
47
48 130 samples containing multiple bacterial species relative to total number of swabs, were calculated
49
50 131 according to swab type, age, recent RTI, recent antibiotic use, vaccination status and geographical
51
52 132 location.

53
54 133

1
2
3
4
5
6
7 134 **Study Costs**

8 135 Total costs associated with each swabbing method were calculated to allow cost comparisons
9
10 136 between methods. Costs were calculated as total costs within a single swabbing group divided by the
11 total number of responders from that swabbing group. This included swab packs sent out to
12 individuals but not used. Costs were separated into laboratory consumables, printing, swabs,
13
14 138 National Health Service (NHS) Service Support Costs (additional healthcare costs due to the research
15
16 139 taking place), transport and postage.
17
18 140

141 RESULTS

142 Participation Rates

143 Eighteen of the 20 GP practices participated in both self- and HCP-swabbing, one participated in self-
144 swabbing only and one dropped out of the study. Participant characteristics are shown in table 1.

145 Overall participation rates were higher in the self-swabbing group at 23.4% ($n=1,260$; $N=5,395$; 95%
146 CI 22.3%–24.5%) compared with the HCP group at 6.2% ($n=314$; $N=5,054$; 95% CI 5.5%–6.9%). Self-
147 swabbing participation rates varied from 9.3% ($n=27$; $N=290$) to 33.1% ($n=96$; $N=290$) between
148 practices whereas HCP participation rates varied from 1.0% ($n=3$; $N=290$) to 12.3% ($n=34$; $N=277$).

149 Ten practices had participation rates $\geq 25\%$ in the self-swabbing group, which was the anticipated
150 level of participation. There was a negative correlation between participation rate and deprivation

151 IMD score in the self-swabbing group ($r=-0.473$, $p=0.041$) and the HCP group ($r=-0.417$, $p=0.085$),

152 which was only significant in the former. Participation was higher in individuals aged ≥ 5 years at 27.8%

153 ($n=931$; $N=3,349$; 95% CI 26.8%–29.3%) in the self-swabbing group and 8.2% ($n=258$; $N=3,146$; 95%

154 CI 7.2%–9.2%) in the HCP group versus 0–4 years at 16.1% ($n=329$; $N=2,045$; 95% CI 14.5%–17.7%) in

155 the self-swabbing group and 2.9% ($n=56$; $N=1,908$; 95% CI 2.2%–3.7%) in the HCP group. The

156 greatest number of responses received was from individuals aged 50–80 years, comprising 41.7%

157 ($n=656$; $N=1,574$) of total participants.

159 Swab Positivity Rates

160 Out of 1,260 self-swabbing participants, 1,254 returned both swabs with labels distinguishing nose

161 from WMS but six individuals failed to label their swabs and thus were excluded from analyses. Out

162 of 314 HCP swabbing participants, 309 had both swabs returned by their GP but five individuals

163 were incorrectly swabbed by their GP and thus were excluded from analyses. Overall the proportion

164 of swabs positive for any one of the six bacterial species (positivity rate) in both study groups was

165 similar at 47.2% ($n=595$) in the self-swabbing group and 48.4% ($n=152$) in the HCP group. Swab

positivity rates were 35.04.8% (n=439; N=1,254; 95% CI 32.42%–37.65%) for NS, 19.16% (n=239; N=1,254; 95% CI 17.416.9%–21.821.3%) for self-taken WMS, 27.425.6% (n=79; N=309; 95% CI 22.520.7%–32.330.5%) for NPS and 344.04% (n=105; N=309; 95% CI 28.78%–399.33%) for HCP-taken WMS (Supplementary Figure 1). The nose swab (NS) and HCP-taken WMS were most effective in detecting carriage of the target organisms. Positivity rates of NS were significantly higher than NPS ($X^2=9.974$, $df=1$, $p=0.002$). Positivity rates of ~~self-taken WMS and~~ HCP-taken WMS were significantly ~~different~~ higher than self-taken WMS ($X^2=35.5732.157$, $df=1$, $p<0.001$).

173

174 **Bacterial Carriage Rates**

175 ~~Culture~~ Carriage rates within each swab type data, in (Figure 1), show few significant differences
 176 between self-swabbing and HCP swabbing. *S. pneumoniae* carriage was similar between NS and NPS
 177 ($X^2=3.403$, $df=1$, $p=0.075$) and between self-taken and HCP-taken WMS (test value=0.139, $df=1$,
 178 $p=0.661$). *M. catarrhalis* carriage was similar between NS and NPS ($X^2=3.757$, $df=1$, $p=0.058$) ~~but~~ but
 179 significantly higher in HCP-taken WMS compared to self-taken WMS ($X^2=43.404$, $df=1$, $p<0.001$). *S.*
 180 *aureus* carriage was significantly greater ~~higher carriage of *S. aureus* in NS than any other swab~~
 181 ~~type~~ NPS ($X^2=13.161$, $df=1$, $p<0.001$) but was similarly low in self-taken and HCP-taken WMS
 182 ($X^2=1.218$, $df=1$, $p=0.315$). *H. influenzae* carriage was similarly low in NS and NPS ($X^2=0.193$, $df=1$,
 183 $p=0.700$) as well as in self-taken and HCP-taken WMS (test value=2.888, $df=1$, $p=0.151$). ~~*S.*~~
 184 *pneumoniae* carriage was detected similarly in NS and NPS, which was significantly greater than
 185 either WMS. Although *H. influenzae* carriage was highest in NS, this was not significantly different
 186 from the other swab types. *M. catarrhalis* carriage was significantly higher in the HCP-taken WMS
 187 when compared with the other swab types. *P. aeruginosa* carriage was similar in NS and NPS (test
 188 value=0.148, $df=1$, $p=1.000$) as well as in self-taken and HCP-taken WMS ($X^2=0.032$, $df=1$, $p=1.000$)
 189 higher in the self-taken WMS but was not significantly different from the other swab types. *N.*
 190 *meningitidis* was not detected in any swab type used in this study.

1
2
3
4
5
6
7 191 We sought to compare the carriage rates of the bacterial species in each swab type. These were
8 192 similar between NS/NPS and between the two WMS, except for *M. catarrhalis* carriage, which
9 193 differed significantly between the two WMS in most age groups, and *S. aureus*, which showed
10 194 significant differences between NS/NPS in individuals aged 18-64 years (Table 4).
11
12
13
14
15

16 196 Co-carriage Rates

17
18 197 Overall co-carriage rates were 3.9% ($n=49$; $N=1,219$; 95% CI 2.8%–5.0%) in NS, 1.10% ($n=13$; $N=1,219$;
19 198 95% CI 0.5%–1.7%) in self-taken WMS, 2.3% ($n=7$; $N=307$; 95% CI 0.6%–4.0%) in NPS and 1.69%
20 199 ($n=56$; $N=307$; 95% CI 0.2%–3.0%) in HCP-taken WMS. In NS and NPS, co-carriage rates were
21 200 significantly higher in individuals aged 0-4 years (NS [9.1%; $n=30$; $N=329$; 95% CI 6.0%–12.2%] and
22 201 NPS [8.9%; $n=5$; $N=56$; 95% CI 1.4%–16.4%]) versus ≥ 5 years (NS [2.1%; $n=19$; $N=907$; 95% CI 1.2%–
23 202 3.0%] and NPS [10.8%; $n=2$; $N=253$; 95% CI 0.2%–3.4%]). Nose co-colonisation decreased with age,
24 203 with 8.0% ($n=11$; $N=137$; 95% CI 3.5%–12.5%) in individuals aged 5-17 years, 1.1% ($n=5$; $N=464$; 95%
25 204 CI 0.2%–2.1%) in individuals aged 18-64 years and 1.0% ($n=3$; $N=306$; 95% CI -0.1%–2.1%) in those
26 205 aged ≥ 65 years. The most common co-colonisation relationship in nose swabs was between *S.*
27 206 *pneumoniae* and *H. influenzae* (50% [$n=15$; $N=30$] in 0-5 years, 26.3% [$n=5$; $N=19$] in ≥ 5 years).
28
29
30
31
32
33
34
35
36
37
38
39

40 208 Association between Demographics and Carriage

41 209 Participant age

42
43 210 Bacterial carriage was highly variable with age, in particular carriage of *S. pneumoniae*, *H. influenzae*
44 211 *M. catarrhalis* and *S. aureus* (Tables 2-3). Carriage rates of *S. pneumoniae* and *H. influenzae* carriage
45 212 in both NS and NPS decreased with age, with 0-4 year olds experiencing the highest carriage rates. *S.*
46 213 *pneumoniae* nasal carriage dropped off significantly after 5 years of age with >2x difference in
47 214 NS and >3x difference in NPS higher in between those aged 0-4 years olds compared with and those
48 215 aged 5-17 years. *S. pneumoniae* carriage in self-taken WMS also showed higher carriage in the young
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 216 (0-4 years and 5-17 years age groups) compared with adults. *H. influenzae* nasal carriage decreased
8
9 217 more steadily with age. *M. catarrhalis* nose carriage was also highest in those aged 0-4 years but
10 218 remained at lower levels in the other age groups. *S. aureus* nose carriage increased sharply ~~in young~~
11 219 ~~children~~ after the age of 5 years but remained high after the age of five in older children and adults. *S.*
12 220 *aureus* nose carriage was >3x higher in participants aged 5-17 years when compared with
13
14 221 participants 0-4 years. ~~*M. catarrhalis* and *P. aeruginosa* were less variable~~ did not vary between the
15
16 222 age groups in any swab type.
17
18
19
20
21
22
23

24 225 Participant questionnaire information

25
26 226 Higher nasal and NP carriage rates of *S. pneumoniae* and *H. influenzae* were observed in participants
27
28 227 who had experienced a recent RTI. *S. pneumoniae* nose carriage was >3x higher in those with recent
29
30 228 RTI versus those without recent RTI, using the Fisher's Exact test ($\chi^2=66.408$, $df=1$, $p<0.001$). *H.*
31
32 229 *influenzae* ~~nasal~~ nose carriage was also >2x higher in those with recent RTI versus those without
33
34 230 recent RTI, using the Chi-squared test ($\chi^2=12.533$, $df=1$, $p=0.001$). Recent antibiotic treatment was
35
36 231 only significant in *P. aeruginosa* NP carriage, where recent antibiotics use was associated with
37 232 increased carriage of this bacterium (test value=9.018, $df=1$, $p=0.037$). ~~And up-to-date~~ vaccination
38
39 233 status ~~were~~ was not associated with significant changes in carriage of any of the target bacteria. Full
40
41 234 results ~~and p-values~~ are shown in Tables 2 and -3. In NS, recent RTI was also associated with higher
42
43 235 co-carriage rates at 8.0% ($n=29$) when compared with no recent RTI at 2.2% ($n=19$). Recent antibiotic
44
45 236 use, vaccination status and geographical location did not appear to affect co-carriage rates.

46 47 237 Geographical location

48
49 238 Carriage rates of the target bacterial species showed some differences according to practice location
50
51 239 (Supplementary Figure 2). Overall bacterial carriage was significantly different by geographical area
52
53 240 in NS ($\chi^2=11.609$, $df=5$, $p=0.04$) and self-taken WMS ($\chi^2=13.900$, $df=5$, $p=0.02$) but not in either HCP
54
55

1
2
3
4
5
6
7 241 swab. However, individual bacteria carriage rates were not significantly different between
8 242 geographical areas.

9
10
11 243 *Deprivation*

12
13 244 Participants attending practices in less deprived locations had slightly higher bacterial carriage rates,
14
15 245 except for *P. aeruginosa*, suggesting a possible negative relationship between deprivation score and
16
17 246 bacterial carriage. However the differences observed were not statistically significant.

18
19 247

20
21 248

22
23 249 **Study Costs**

24
25 250 Overall, total costs per participant were over a third lower in the self-swabbing group at £41.21
26
27 251 (\$67.92) versus the HCP group at £69.66 (\$114.82) (Table 1). NHS service support costs made up a
28
29 252 large proportion of the difference between the two study groups, representing 56.7%
30
31 253 (£39.52/person) of costs in the HCP group but only 6.8% (£2.81/person) of costs in the self-swabbing
32
33 254 group.

255 **DISCUSSION**

256 Our study demonstrates that self-swabbing is as effective in detecting bacterial pathogens in the
257 respiratory tract as HCP swabbing and that nose swabs could be used more routinely to detect the
258 presence of bacterial pathogens *S. pneumoniae*, *H. influenzae*, *S. aureus* and *P. aeruginosa*. Whole
259 mouth swabs, on the other hand, are the most sensitive swab for detection of *M. catarrhalis*. The
260 swabs used in this study were not sensitive for detection of *N. meningitidis*.~~Few studies have~~
261 ~~simultaneously described the carriage rates of multiple bacterial species within the respiratory tract~~
262 ~~and, to our knowledge, none have reported bacterial carriage in a large population based study~~
263 ~~across all age groups. This study aimed to address this information gap in order to generate greater~~
264 ~~insight into the complexities of microbial respiratory carriage. This involved undertaking a large~~
265 ~~community based respiratory tract carriage study by recruiting participants from 20 GP practices~~
266 ~~from a single geographical area in Southern England. Different studies have previously reported~~
267 ~~carriage rates from divergent swabbing sites, making comparisons between these studies difficult.~~
268 ~~We compared multiple swabbing sites in order to assess the most effective way of sampling the~~
269 ~~human respiratory tract flora in the hope to provide information for implementation of a~~
270 ~~standardised swabbing method.~~

271 Higher participation rates within the self-swabbing group compared with the HCP group highlight
272 the willingness of ~~patients~~ individuals to participate in such studies when the process is facilitated.
273 The very low participation rate of the HCP group would render this method invalid for large-scale
274 studies. Whilst the responsiveness of the self-swabbing group was higher, it was still less than the
275 anticipated 25%, meaning there will always be a problem of non-response bias. However, similar
276 carriage rates were observed in our study when compared with previous swabbing studies,
277 demonstrating that our sample size is large enough to overcome differences that may result from
278 non-response bias. Barriers to participation in the HCP group might include the amount of time
279 required for organising and attending swabbing appointments and the slight discomfort experienced

1
2
3
4
5
6
7 280 during nasopharyngeal swabbing. Self-swabbing overcame many of these barriers by offering a
8
9 281 relatively straightforward, rapid and easy alternative. High participation rates in elderly participants
10
11 282 might be a result of their increased availability for participation and their increased chance of
12
13 283 exposure to RTI allowing them to relate to the study aims. ~~Younger participants, on the other hand,~~
14
15 284 ~~may have a different attitude towards participation.~~ Parents may also be reluctant to swab their
16
17 285 children if they are very young. The negative correlation between participation rates and deprivation
18
19 286 highlights certain barriers associated with high levels of deprivation, which have been observed in
20
21 287 other studies [25].

22
23 288 Swab positivity rates and bacterial carriage rates indicate that ~~the NS was most sensitive in self-~~
24
25 289 ~~swabbing is as effective as HCP swabbing in~~ sampling microbial species within the airways of the
26
27 290 general population within our large population-based study. Higher positivity rates in NS versus NPS
28
29 291 and higher carriage of *S. aureus* within NS versus NPS demonstrate the potential for using a self-
30
31 292 taken NS rather than HCP-taken NPS to detect respiratory pathogens. Although HCP swabbing was
32
33 293 highly sensitive, as demonstrated by a significantly higher positivity rates infor HCP-taken WMS
34
35 294 versus self-taken WMS and higher carriage of *M. catarrhalis* within HCP-taken WMS demonstrate
36
37 295 the sensitivity of HCP-swabbing. However, lower participation rates with fewer children and more
38
39 296 elderly participants within this group HCP swabbing have most probably resulted in reduced carriage
40
41 297 rates within NPS. Self-swabbing allowed the recruitment of a greater spread of age groups, which is
42
43 298 essential for obtaining a true estimate of carriage. Very low participation ~~rates~~ in the HCP group is
44
45 299 ~~are~~ problematic for assessing carriage within the general population as fewer numbers of samples
46
47 300 can be obtained and the cost of obtaining them is high. In order to obtain the same spread of ages as
48
49 301 the self-swabbing group, a much larger number of individuals would need to be invited. These high
50
51 302 costs of HCP swabbing are mainly due to the operation of swabbing clinics. In order to increase
52
53 303 participation, healthcare providers could undertake verbal encouragement or study advertisement
54
55 304 in practice. WMS were efficient in isolating *M. catarrhalis* and *P. aeruginosa*, however, large
56
57 305 amounts of background flora within this site and low isolation levels for the other bacteria render

1
2
3
4
5
6
7 306 this swab less efficient on the whole. The lack of isolation of *N. meningitidis* may be due to the type
8
9 307 of swabs used, as oropharyngeal swabs are often preferred [26]. Low response rates from teenagers,
10
11 308 the most frequent carriers of *N. meningitidis*, may also have caused the lack of isolation of this
12
13 309 species [27].

14
15 310 Carriage rates of five out of the six target organisms follow previously observed patterns with *S.*
16
17 311 *pneumoniae* and *H. influenzae* being carried predominantly in young children and *S. aureus* being
18
19 312 carried more in older children and adults [12, 28, 29]. *M. catarrhalis* and *P. aeruginosa* carriage rates
20
21 313 were constant across all age groups demonstrating that carriage of these organisms is unaffected by
22
23 314 age. *N. meningitidis* carriage did not follow previously observed patterns as no isolates were
24
25 315 detected. However, the number of participants in the study may not have been large enough to
26
27 316 detect any isolates with 95% confidence. Furthermore, swab types used and turn-around times from
28
29 317 swabbing to sample processing may not be optimal for *N. meningitidis* recovery. The effect of recent
30
31 318 RTI on carriage of *S. pneumoniae* and *H. influenzae* is one that might be expected as colds and flu
32
33 319 weaken host immunity allowing for carriage by these organisms [30]. The lack of an apparent effect
34
35 320 of vaccination status is potentially due to herd immunity, as unvaccinated people benefit from
36
37 321 protection from disease as a result of a largely vaccinated population [31]. However, further details
38
39 322 of vaccines received via a access to individual participant immunisation records in future studies
40
41 323 might enable improved assessment of the effects of immunisation on carriage of target and non-
42
43 324 target bacteria.

44
45 325 This pilot study has also enabled all aspects of study set-up through to completion to be tried and
46
47 326 tested, which will be essential for setting up larger swabbing studies. Study documentation, study
48
49 327 protocol, ethics application and sample size calculations have been trialled and alterations can now
50
51 328 be preformed on further studies in order to improve outcomes and efficiency. Limitations, including
52
53 329 numbers of non-responses, can be improved in further studies in order to increase confidence in
54
55 330 study outcomes.

1
2
3
4
5
6
7 331 The results from this pilot study have allowed the comparison of swabbing methodologies for
8
9 332 determining carriage of the targeted bacterial species within the respiratory tract. The advantages of
10
11 333 self-swabbing are evident with higher responsiveness and lower costs than HCP swabbing. Further
12
13 334 assessment will determine whether our findings are applicable to other geographical locations, over
14
15 335 time and to a wider array of bacterial species. Such assessment would help to refine methodologies,
16
17 336 which will be key to obtaining a precise understanding of bacterial carriage in the respiratory tract.

18 337 ~~By determining carriage rates in different age groups, the study has enabled the determination of at-~~
19
20 338 ~~risk populations which is key to developing efficient vaccination and antibiotic strategies.~~

Funding

This work was supported by the Rosetrees Trust [M141 to S.C.C.] and the Bupa Foundation [TBF-M11-019 to S.C.C.].

Conflicts of Interest

S.N.F. receives support from the National Institute for Health Research funding via the Southampton NIHR Wellcome Trust Clinical Research Facility and the Southampton NIHR Respiratory Biomedical Research Unit. J.M.J. has received consulting fees from GlaxoSmithKline. S.N.F. acts as principal investigator for clinical trials conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receives no personal payments from them. S.N.F. has participated in advisory boards for vaccine manufacturers but receives no personal payments for this work. S.C.C. currently receives unrestricted research funding from Pfizer Vaccines (previously Wyeth Vaccines) and has participated in advisory boards and expert panels for GSK, Pfizer and Novartis. S.C.C. is an investigator on studies conducted on behalf of University Hospital Southampton NHS Foundation Trust / University of Southampton / Public Health England that are sponsored by vaccine manufacturers but receives no personal payments from them. S.N.F., S.C.C. and J.M.J. have received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. All other authors have no conflicts of interest.

Author Contributions and Acknowledgments

ALC: Study set-up, data collection, data analysis and writing; RNW: Study set-up, data collection, proof-reading of manuscript; NB: Data collection, proof-reading of manuscript; RA: Data collection, proof-reading of manuscript; AT: Study design, data collection, proof-reading of manuscript; SNF: Study design, data analysis, proof-reading of manuscript; JMJ: Study design, data analysis, proof-

1
2
3
4
5
6
7 reading of manuscript; HMY: Study design, data analysis, proof-reading of manuscript; PJR: Study
8 design, data analysis, proof-reading of manuscript; MAM: Study design, data analysis, proof-reading
9 of manuscript; MVM: Study design, data analysis, proof-reading of manuscript; SCC: Study design,
10 data collection, data analysis, proof-reading of manuscript.
11
12
13

14
15 We thank Shabana Hussain [and Karen Cox](#) for technical assistance throughout the study. We also
16 thank the Bupa Foundation for providing the funding to SCC in order to undertake the study and the
17 Rosetrees Trust for their funding contribution for ALC's PhD studentship. We thank the
18 Southampton NIHR Wellcome Trust Clinical Research Facility for part-funding SNF. We also thank the
19 National Institute for Health Research Comprehensive Local Research Network (NIHR CLRN), NHS
20 Service Support Costs, Solent Primary Care Trust (PCT), South West (East Hub) Primary Care
21 Research Network (PCRN) and Danvers International for their contributions.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bogaert, D., et al., *Variability and diversity of nasopharyngeal microbiota in children: a metagenomic analysis*. PLoS One, 2011. **6**(2): p. e17035.
2. Faden, H., et al., *Relationship between Nasopharyngeal Colonization and the Development of Otitis Media in Children*. J Infect Dis, 1997. **175**: p. 1440-1445.
3. Brueggemann, A.B., et al., *Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential*. J Infect Dis, 2003. **187**(9): p. 1424-32.
4. Lozano, R., et al., *Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010*. Lancet, 2012. **380**(9859): p. 2095-128.
5. Akmatov, M.K., et al., *E-mail-based symptomatic surveillance combined with self-collection of nasal swabs: a new tool for acute respiratory infection epidemiology*. Int J Infect Dis, 2011. **15**(11): p. e799-803.
6. Leach, A.J., et al., *Comparison of nasal swabs with nose blowing for community-based pneumococcal surveillance of healthy children*. J Clin Microbiol, 2008. **46**(6): p. 2081-2.
7. Lieberman, D., et al., *Nasopharyngeal versus oropharyngeal sampling for isolation of potential respiratory pathogens in adults*. J Clin Microbiol, 2006. **44**(2): p. 525-8.
8. Trotter, C.L. and N.J. Gay, *Analysis of longitudinal bacterial carriage studies accounting for sensitivity of swabbing: an application to Neisseria meningitidis*. Epidemiol Infect, 2003. **130**(2): p. 201-205.
9. Watt, J.P., et al., *Nasopharyngeal versus oropharyngeal sampling for detection of pneumococcal carriage in adults*. J Clin Microbiol, 2004. **42**(11): p. 4974-6.
10. Rapola, S., et al., *Comparison of Four Different Sampling Methods for Detecting Pharyngeal Carriage of Streptococcus pneumoniae and Haemophilus influenzae in Children*. J Clin Microbiol, 1997. **35**(5): p. 1077-1079.
11. Greenberg, D., et al., *Relative importance of nasopharyngeal versus oropharyngeal sampling for isolation of Streptococcus pneumoniae and Haemophilus influenzae from healthy and sick individuals varies with age*. J Clin Microbiol, 2004. **42**(10): p. 4604-9.
12. Gamblin, J., et al., *Nasal self-swabbing for estimating the prevalence of Staphylococcus aureus in the community*. J Med Microbiol, 2013. **62**(Pt 3): p. 437-40.
13. Satzke, C., et al., *Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: Updated recommendations from the World Health Organization Pneumococcal Carriage Working Group*. Vaccine, 2013. **32**(1): p. 165-179.
14. Akmatov, M.K., et al., *Equivalence of self- and staff-collected nasal swabs for the detection of viral respiratory pathogens*. PLoS One, 2012. **7**(11): p. e48508.
15. de Roux, A., et al., *Mixed community-acquired pneumonia in hospitalised patients*. Eur Respir J, 2006. **27**(4): p. 795-800.
16. Harro, C.D., et al., *The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies*. Vaccine, 2012. **30**(9): p. 1729-36.
17. Moore, R., et al., *Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection*. Hum Vaccin Immunother, 2012. **9**(3): p. Published ahead of print.
18. Serruto, D., et al., *The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens*. Vaccine, 2012. **30** Suppl 2: p. B87-97.
19. Sheldon, E., et al., *A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults*. Hum Vaccin Immunother, 2012. **8**(7): p. 888-895.

- 1
- 2
- 3
- 4
- 5
- 6
- 7 20. Skinner, J.M., et al., *Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model*. *Vaccine*, 2011. **29**(48): p. 8870-6.
- 8
- 9 21. Tocheva, A.S., et al., *Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children*. *Vaccine*, 2011. **29**(26): p. 4400-4.
- 10
- 11 22. Government, D.f.C.a.L., *English indices of deprivation 2010*, Department for Communities and Local Government, Editor. 2011: London, UK.
- 12
- 13 23. Chapman, K.E., D. Wilson, and R. Gorton, *Invasive pneumococcal disease and socioeconomic deprivation: a population study from the North East of England*. *J Public Health (Oxf)*, 2013. **35**(4): p. 558-69.
- 14
- 15 24. ESRI, *ArcGIS 10.1*. 2012, ESRI: Redlands, California.
- 16
- 17 25. Sheron, N., et al., *Feasibility of detection and intervention for alcohol-related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS)*. *Br J Gen Pract*, 2013. **63**(615): p. e698-705.
- 18
- 19 26. Olcen, P., et al., *Culture diagnosis of meningococcal carriers: yield from different sites and influence of storage in transport medium*. *J Clin Pathol*, 1979. **32**(12): p. 1222-5.
- 20
- 21 27. Cartwright, K.A., et al., *The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica*. *Epidemiol Infect*, 1987. **99**(3): p. 591-601.
- 22
- 23 28. Gray, B.M., G.M. Converse, 3rd, and H.C. Dillon, Jr., *Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life*. *J Infect Dis*, 1980. **142**(6): p. 923-33.
- 24
- 25 29. Peltola, H., T. Kilpi, and M. Anttila, *Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines*. *Lancet*, 1992. **340**(8819): p. 592-4.
- 26
- 27 30. Brundage, J.F., *Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness*. *Lancet Infect Dis*, 2006. **6**(5): p. 303-312.
- 28
- 29 31. Ramsay, M.E., et al., *Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis*. *BMJ*, 2003. **326**(7385): p. 365-6.
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Table 1. Participant Characteristics and Study Costs (in British Pounds) for Self-swabbing and HCP swabbing

	Participant characteristics n(%) and costs per participant (£)	
	Self-swabbing	HCP swabbing
Age (years)		
Mean	37.42	50.09
Minimum	0	0
Maximum	94	88
0-4	329 (26.1)	56 (17.8)
5-17	137 (10.9)	24 (7.6)
18-64	465 (36.9)	89 (28.3)
65+	311 (24.7)	145 (46.2)
Missing	18 (1.4)	0 (0.0)
Recent Antibiotic Treatment		
Yes	101 (8.0)	26 (8.3)
No	1124 (89.2)	286 (91.1)
Unknown/Missing	35 (2.8)	2 (0.6)
Recent Respiratory Infection		
Yes	365 (29.0)	61 (19.4)
No	860 (68.3)	250 (79.6)
Unknown/Missing	35 (2.8)	3 (1.0)
Vaccination Status		
Up-to-date	1022 (81.1)	270 (86.0)
Not up-to-date	40 (3.2)	10 (3.2)
Unknown/Missing	198 (15.7)	34 (10.8)
Costs per participant (£)		
Laboratory consumables	8.06	8.47
Printing	2.14	7.23
Swabs and swab packs	17.08	9.65
Service Support Costs (SSC)	2.81	39.52
Transport (by taxi or internal mail)	0.00	4.78
Postage	11.12	0.00
Total	41.21	69.66

Costs (British Pounds-Sterling) are per participant taking into account wastage of swabs and swab packs; HCP = Healthcare professional.

Table 2. Bacterial Nose and Nasopharyngeal Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *S. aureus*, *H. influenzae* and *P. aeruginosa* by Participant Age Group, Recent RTI, Recent Antibiotic Treatment and Vaccination Status

Carriage of Bacterial Species within Nose and Nasopharyngeal Swabs in different Participant Categories

Category	Participants (N)		% (n) (95% CI)											
	SS	HCP	<i>S. pneumoniae</i>		<i>H. influenzae</i>		<i>M. catarrhalis</i>		<i>S. aureus</i>		<i>P. aeruginosa</i>			
			Nose	NP	Nose	NP	Nose	NP	Nose	NP	Nose	NP		
Age (years)														
0-4	329	56	32.8(108) (27.7, 37.9)	33.9(19) (21.5, 46.3)	7.3(24) (4.5, 10.1)	10.7(6) (2.6, 18.8)	5.8(19) (3.3, 8.3)	10.7(6) (2.6, 18.8)	9.7(32) (6.5, 12.9)	5.4(3) (-0.5, 11.3)	2.7(9) (1.0, 4.5)	1.8(1) (-1.7, 5.3)		
5-17	137	22	13.1(18) (7.5, 18.8)	9.1(2) (-2.9, 21.1)	5.1(7) (1.4, 8.8)	0.0(0) N/A	0.7(1) (-0.7, 2.1)	4.5(1) (-4.1, 13.2)	35.0(48) (27.0, 43.0)	13.6(3) (-0.7, 27.9)	0.7(1) (-0.7, 2.1)	0.0(0) N/A		
18-64	464	88	1.1(5) (0.2, 2.1)	0.0(0) N/A	0.2(1) (-0.2, 0.6)	1.1(1) (-1.1, 3.3)	1.5(7) (0.4, 2.6)	3.4(3) (-0.4, 7.2)	24.8(115) (20.9, 28.7)	11.4(10) (4.8, 18.0)	1.3(6) (0.3, 2.3)	1.1(1) (-1.1, 3.3)		
65+	306	143	2.0(6) (0.4, 3.6)	1.4(2) (-0.5, 3.3)	0.7(2) (-0.2, 1.6)	0.0(0) N/A	1.3(4) (0.0, 2.6)	2.8(4) (0.1, 5.5)	23.2(71) (18.5, 27.9)	15.4(22) (9.5, 21.3)	1.0(3) (-0.1, 2.1)	1.4(2) (-0.5, 3.3)		
<i>p</i>			<0.001*	<0.001	<0.001	<0.001	0.001	0.100	<0.001*	0.263	0.288	1.000		
Recent Respiratory Tract Infection														
Yes	363	59	22.3(81) (18.0, 26.6)	15.3(9) (6.1, 24.5)	5.2(19) (2.9, 7.5)	6.8(4) (0.4, 13.2)	3.6(13) (1.7, 5.5)	3.4(2) (-1.2, 8.0)	19.3(70) (15.2, 23.4)	6.8(4) (0.4, 13.2)	2.2(8) (0.7, 3.7)	3.4(2) (-1.2, 8.0)		
No	856	247	6.3(54) (4.7, 7.9)	5.7(14) (2.8, 8.6)	1.6(14) (0.8, 2.4)	1.2(3) (-0.2, 2.6)	2.1(18) (1.1, 3.1)	4.9(12) (2.2, 7.6)	22.3(191) (19.5, 25.1)	13.8(34) (9.5, 18.1)	1.3(11) (0.5, 2.1)	0.8(2) (-0.3, 1.9)		
<i>p</i>			<0.001*	0.023	0.001*	0.028	0.163*	1.000	0.253*	0.188*	0.310*	0.169		
Recent use of Antibiotics														
Yes	101	26	5.9(6) (1.3, 10.5)	3.8(1) (-3.6, 11.2)	1.0(1) (-0.9, 2.9)	0.0(0) N/A	1.0(1) (-0.9, 2.9)	3.8(1) (-3.6, 11.2)	15.8(16) (8.7, 22.9)	0.0(0) N/A	1.0(1) (-0.9, 2.9)	7.7(2) (-2.6, 18.0)		
No	1118	281	11.5(129) (9.6, 13.4)	7.8(22) (4.7, 10.9)	2.9(32) (1.9, 3.9)	2.5(7) (0.7, 4.3)	2.7(30) (1.8, 3.7)	4.6(13) (2.2, 7.1)	21.7(243) (19.3, 24.1)	13.5(38) (9.5, 17.5)	1.5(17) (0.8, 2.2)	0.7(2) (-0.3, 1.7)		
<i>p</i>			0.097*	0.706	0.515	1.000	0.508	1.000	0.203*	0.056	1.000	0.037		
Vaccinations up-to-date														
Yes	1017	265	12.8(130) (10.8, 14.9)	8.7(23) (5.3, 12.1)	3.0(31) (2.0, 4.1)	2.6(7) (0.7, 4.5)	2.8(28) (1.8, 3.8)	4.5(12) (2.0, 7.0)	20.4(207) (17.9, 22.9)	13.2(35) (9.1, 17.3)	1.6(16) (0.8, 2.4)	1.5(4) (0.0, 3.0)		
No	40	10	5.0(2) (-1.8, 11.8)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	10.0(1) (-8.6, 28.6)	25.0(10) (11.6, 38.4)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A		
<i>p</i>			0.219	1.000	1.000	1.000	1.000	0.389	0.548*	0.621	0.484	1.000		

1
2
3
4
5
6
7 Chi-squared (indicated by *) and Fisher's exact tests for independence were used to determine significant differences between bacterial carriage rates in different age
8 groups, with/without recent RTI, with/without recent antibiotic treatment and with/without an up-to-date vaccination status. P-values are 2-tailed, significant values are
9 highlighted in bold. 95% CI are written as (upper CI, lower CI). NP = Nasopharyngeal swab. N/A = not applicable.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3. Bacterial Self-taken and HCP-taken Whole Mouth Swab Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *S. aureus*, *H. influenzae* and *P. aeruginosa* by Participant

Age Group, Recent RTI, Recent Antibiotic Treatment and Vaccination Status

Category	Participants (N)		Carriage of Bacterial Species within Mouth Swabs in different Participant Categories									
	SS	HCP	<i>S. pneumoniae</i>		<i>H. influenzae</i>		<i>M. catarrhalis</i>		<i>S. aureus</i>		<i>P. aeruginosa</i>	
			Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS	Self-taken WMS	HCP-taken WMS
Age (years)												
0-4	329	56	1.2(4) (0.0, 2.4)	3.6(2) (-1.3, 8.5)	1.2(4) (0.0, 2.4)	5.4(3) (-0.5, 11.3)	11.9(39) (8.4, 15.4)	35.775(204) (24.823.2) 50.248.3	2.4(8) (0.8, 4.1)	0.0(0) N/A	4.9(16) (2.6, 7.2)	3.6(2) (-1.3, 8.5)
5-17	137	22	1.5(2) (-0.5, 3.5)	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	11.7(16) (6.3, 17.1)	27.331.8(62) (42.38.7) 51.345.9	4.4(6) (1.0, 7.8)	4.5(1) (-4.2, 13.2)	3.6(5) (0.5, 6.7)	0.0(0) N/A
18-64	464	88	0.0(0) N/A	0.0(0) N/A	0.9(4) (0.0, 1.8)	1.1(1) (-1.1, 3.3)	15.39(714) (12.0.5.6) 18.69.2 13.14.7(40)	22.73.9(204) (15.014.0) 32.831.5	3.0(14) (1.5, 4.6)	2.3(2) (-0.8, 5.4)	1.7(8) (0.5, 2.9)	2.3(2) (-0.8, 5.4)
65+	3064	143	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	0.7(1) (-0.7, 2.1)	5 (10.79.3) 18.716.9	30.12.2(436) (24.522.6) 39.937.6	1.6(5) (0.2, 3.0)	1.4(2) (-0.5, 3.3)	2.9(9) (1.0, 4.8)	3.5(5) (0.5, 6.5)
<i>p</i>			0.006	0.063	0.204	0.159	0.476330*	0.348390*	0.361	0.377	0.079	0.910
Recent Respiratory Tract Infection												
Yes	363	59	0.8(3) (-0.1, 1.7)	1.7(1) (-1.6, 5.0)	0.8(3) (-0.1, 1.7)	1.7(1) (-1.6, 5.0)	41.010.5(3) 840 (7.48) 14.213.7 15.414.7(1)	28.825.4(171) 5 (17.314.3) 40.436.5 31.229.6(777)	2.5(9) (0.9, 4.1)	0.0(0) N/A	3.9(14) (1.9, 5.9)	5.1(3) (-0.5, 10.7)
No	856	247	0.4(3) (0.0-0.8)	0.4(1) (-0.4, 1.2)	0.6(5) (0.1, 1.1)	1.6(4) (0.0, 3.2)	26432) (13.012.3) 17.81	3) (25.423.9) 37.035.3	2.7(23) (1.6, 3.8)	1.6(4) (0.0, 3.2)	2.8(24) (1.7, 3.9)	2.4(6) (0.5, 4.3)
<i>p</i>			0.370	0.349	0.701	1.000	0.048054*	0.756632*	0.850*	1.000	0.368*	0.382
Recent use of Antibiotics												
Yes	101	26	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	0.0(0) N/A	14.9(15) (8.0, 21.8)	26.923.1(67) (9.96.9) 43.939.3	3.0(3) (-0.3, 6.3)	3.8(1) (-3.6, 11.2)	2.0(2) (-0.7, 4.7)	3.8(1) (-3.6, 11.2)

Formatted Table

Formatted: None, Indent: Left: 0", Space Before: 0 pt, After: 0 pt, Add space between paragraphs of the same style, Line spacing: single, Don't keep with next, Don't keep lines together

Formatted: Font: Not Italic, Font color: Auto

No	1118	281	0.5(6) (0.1, 0.9)	0.7(2) (-0.3, 1.7)	0.7(8) (0.2, 1.2)	1.8(5) (0.3, 3.4)	14.1 13.4 (1 508) (12.4, 11.4) 16.1 15.4)	31.0 29.2 (827) (25.6, 23.9) 36.4 34.5)	2.6(29) (1.7, 3.5)	1.4(4) (0.0, 2.8)	3.2(36) (2.2, 4.2)	2.8(8) (0.9, 4.7)
<i>p</i>			1.000	1.000	1.000	1.000	0.88 0.761 *	0.82 0.652 *	0.744	0.360	0.764	0.554
Vaccinations up-to-date												
Yes	1017	265	0.6(6) (0.1, 1.1)	0.8(2) (-0.3, 1.9)	0.6(6) (0.1, 1.1)	1.9(5) (0.3, 3.5)	14.3 13.7 (4 45139) (12.2, 11.6) 16.5 15.8)	31.3 29.4 (837 8) (25.7, 23.9) 36.9 34.9)	2.8(28) (1.8, 3.8)	1.5(4) (0.0, 3.0)	3.2(33) (2.1, 4.3)	3.0(8) (1.0, 5.1)
No	40	10	0.0(0) N/A	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A	5.0(2) (-1.8, 11.8)	50.0(5) (19.0, 81.0)	2.5(1) (-2.3, 7.3)	0.0(0) N/A	2.5(1) (-2.3, 7.3)	0.0(0) N/A
<i>p</i>			1.000	1.000	0.237	1.000	0.10 0.153 *	0.17 0.299	1.000	1.000	1.000	1.000

Chi-squared (indicated by *) and Fisher's exact tests for independence were used to determine significant differences between bacterial carriage rates in different age groups, with/without recent RTI, with/without recent antibiotic treatment and with/without an up-to-date vaccination status. P-values are 2-tailed, significant values are highlighted in bold. 95% CI are written as (upper CI, lower CI). WMS = whole mouth swab. N/A = not applicable.

Table 4. Differences in Bacterial Carriage Rate of *S. pneumoniae*, *M. catarrhalis*, *S. aureus*, *H. influenzae* and *P. aeruginosa* between Swab Types According to Age, Recent RTI, Recent Antibiotic Treatment and Vaccination Status


Category	Bacterial Species Carriage Differential between Swab Types									
	<i>S. pneumoniae</i>		<i>H. influenzae</i>		<i>M. catarrhalis</i>		<i>S. aureus</i>		<i>P. aeruginosa</i>	
	Nose—NP	SS-WMS—HCP-WMS	Nose—NP	SS-WMS—HCP-WMS	Nose—NP	SS-WMS—HCP-WMS	Nose—NP	SS-WMS—HCP-WMS	Nose—NP	SS-WMS—HCP-WMS
Age (years)										
0-4	-1.1 (-2.1, -0.1) 0.879*	-2.4 (-3.9, -0.9) 0.212	-3.4 (-5.2, -1.6) 0.416	-4.2 (-6.2, -2.2) 0.067	-4.9 (-7.1, -2.7) 0.234	-23.8 5.6 (-28.1, 30.0) 16.9 21.2) <0.001*	4.3 (2.3, 6.3) 0.333*	2.4 (0.9, 3.9) 0.609	0.9 (0.0, 1.8) 1.000	1.3 (0.2, 2.4) 1.000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

5-17	4.0 (1.0,7.0) 1.000	1.5 (-0.4,3.4) 1.000	5.1 (1.7,8.5) 0.594	0.0 N/A N/A	-3.8 (-6.8,-0.9) 0.258	-15.620.1 (-21.26.3) 10.013.9) 0.08821	21.4 (15.0,27.8) 0.051*	-0.1 (-0.6,0.4) 1.000	0.7 (-0.6,2.0) 1.000	3.6 (0.7,6.5) 1.000
18-64	1.1 (-0.2,2.0) 1.000	0.0 N/A N/A	-0.9 (-1.7,-0.1) 0.294	-0.2 (-0.6,0.2) 0.582	-1.9 (-3.0,-0.8) 0.203	-7.48.0 (-9.610.3) 5.27) 0.116089*	13.4 (10.6,16.2) 0.008*	0.7 (0.0,1.4) 1.000	0.2 (-0.2,0.6) 1.000	-0.6 (-1.2,0.0) 0.665
65+	0.6 (-0.1,1.3) 1.000	0.0 N/A N/A	0.7 (-0.1,1.5) 1.000	-0.7 (-1.5,0.1) 0.318	-1.5 (-2.6,-0.4) 0.272	-17.05 (-20.51.0) 12.54.0) <0.001*	7.8 (5.3,10.3) 0.061*	0.2 (-0.2,0.6) 1.000	-0.4 (-1.0,0.2) 0.656	-0.6 (-1.3,0.1) 0.774
Recent Respiratory Tract Infection										
Yes	7.0 (4.6,9.4) 0.237*	-0.9 (-1.8,0.0) 0.454	-1.6 (-2.8,-0.4) 0.546	-0.9 (-1.8,0.0) 0.454	0.2 (-0.2,0.6) 1.000	-14.07.8 (-18.321.5) 11.54.2) 0.0031*	12.5 (9.3,15.7) 0.016*	2.5 (1.0,4.0) 0.620	-1.2 (-2.2,-0.2) 0.637	-1.2 (-2.2,-0.2) 0.718
No	0.6 (0.2,1.1) 0.766*	0.0 N/A N/A	0.4 (0.0,0.8) 0.777	-1.0 (-1.6,-0.4) 0.120	-2.8 (-3.8,-1.8) 0.026*	-14.05.8 (-178.0) 12.83.7) <0.001*	8.5 (6.9,10.1) 0.003*	1.1 (0.5,1.7) 0.369*	0.5 (0.1,0.9) 0.744	0.4 (0.0,0.8) 0.829*
Recent use of Antibiotics										
Yes	2.1 (-0.4,4.6) 1.000	0.0 N/A N/A	1.0 (-0.7,2.7) 1.000	0.0 N/A N/A	-2.8 (-5.7,0.1) 0.369	-8.212.0 (-12.07.7) 3.46.4) 0.275176	15.8 (9.5,22.1) 0.041	-0.8 (-2.4,0.8) 1.000	-6.7 (-11.1,-2.4) 0.106	-1.8 (-4.1,0.5) 0.500
No	3.7 (2.7,4.7) 0.085*	-0.2 (-0.4,0.0) 0.665	0.4 (0.1,0.7) 0.842*	-1.1 (-1.7,-0.6) 0.153	-1.9 (-2.6,-1.2) 0.119*	-15.86.9 (-17.78.9) 13.4.9) <0.001*	8.2 (6.8,9.6) 0.003*	1.2 (0.6,1.8) 0.282*	0.8 (0.3,1.3) 0.396	0.4 (0.1,0.7) 0.850*
Vaccinations up-to-date										
Yes	4.1 (3.0,5.2) 0.071*	-0.2 (-0.4,0.0) 0.673	0.4 (0.1,0.8) 0.841*	-1.3 (-1.9,-0.7) 0.056	-1.7 (-2.4,-1.0) 0.163*	-15.77.0 (-17.699.1) 12.74.9) 12.74.9) <0.001*	7.2 (5.8,8.6) 0.008*	1.3 (0.7,1.9) 0.280*	0.1 (-0.1,0.3) 1.000	0.2 (0.0,0.4) 1.000*
No	5.0 (-1.0,11.0) 1.000	0.0 N/A N/A	2.5 (-1.8,6.8) 1.000	2.5 (-1.8,6.8) 1.000	-7.5 (-14.8,-0.2) 0.363	-45.0 (-58.8,-31.2) 0.002	25.0 (13.0,37.0) 0.179	2.5 (-1.8,6.8) 1.000	2.5 (-1.8,6.8) 1.000	2.5 (-1.8,6.8) 1.000

1
2
3
4
5
6
7 Chi squared (indicated by *) and Fisher's exact tests for independence were used to determine significant differences between bacterial carriage rates in different swab
8 types according to age, recent RTI, recent antibiotic treatment and vaccination status. P-values are 2-tailed, significant values are highlighted in bold. WMS = whole-mouth
9
10 swab, NP = Nasopharyngeal swab.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only



1
2
3
4
5
6
7 **Figure 1.** Bacterial Carriage Rates (%) of (A) *S. pneumoniae* (B) *M. catarrhalis* (C) *S. aureus* (D) *H. influenzae* (E) *P.*
8
9 *aeruginosa* by Swab Method and Site

10 Graphs are bar charts representing carriage frequencies as percentages. Error bars represent 95% Confidence Intervals.

11 ~~Striped boxes represent nose swabs, white boxes represent self taken WMS, dotted boxes represent NP swabs and~~
12
13 ~~grey boxes represent HCP taken WMS.~~
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1. Bacterial Carriage Rates (%) of (A) *S. pneumoniae* (B) *M. catarrhalis* (C) *S. aureus* (D) *H. influenzae* (E) *P. aeruginosa* by Swab Method and Site

Graphs are bar charts representing carriage frequencies as percentages. Error bars represent 95% Confidence Intervals.


190x254mm (300 x 300 DPI)

Supplementary File



Supplementary Figure 1. Total Positivity Rates of the Four Swab Types

Bar chart showing positivity rates for all four swab types. WMS = whole mouth swab, NP = nasopharyngeal swab. Error bars represent 95% confidence intervals. Numbers of positive swabs are shown above each bar.



Supplementary Figure 2. Total Bacterial Carriage Rates of *S. pneumoniae*, *M. catarrhalis*, *P. aeruginosa*, *S. aureus* and *H. influenzae* in all swab types by geographical location of practices

Pie charts represent total bacterial carriage rates (%) in each GP practice with size representing proportionate amounts of bacterial carriage. Percentages of each bacterium within the total carriage rate are represented by coloured sections within each pie chart. Red lines are major roads, blue lines are rivers and darker areas of land represent cities.

Supplementary Table 1. Microbiology Identification Techniques for the Six Target
Bacterial Species

Bacterial species	Identification Technique
<i>S. pneumoniae</i>	Characteristic gram-positive alpha-haemolytic optochin-sensitive colonies growing on blood agar with nalidixic acid.
<i>H. influenzae</i>	Characteristic small gram-negative colonies requiring X+V factors growing on chocolate blood agar with bacitracin.
<i>M. catarrhalis</i>	Characteristic gram-negative tributyrin test-positive, DNase-positive diplococci growing on blood agar.
<i>P. aeruginosa</i>	Characteristic gram-negative oxidase-positive green colonies growing on <i>Pseudomonas</i> -selective CFC agar.
<i>S. aureus</i>	Characteristic gram-positive coagulase-positive colonies growing on blood agar.
<i>N. meningitidis</i>	Characteristic oxidase-positive gram-negative diplococci growing on <i>Neisseria</i> -selective GC agar and matching the correct API NH profile.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7-8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	10-11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10-11
Bias	9	Describe any efforts to address potential sources of bias	7-8
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	9
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7 and 12
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	24
		(b) Indicate number of participants with missing data for each variable of interest	24
Outcome data	15*	Report numbers of outcome events or summary measures	12 and 13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12 and 13
		(b) Report category boundaries when continuous variables were categorized	24
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14-15
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	17-19
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19
Generalisability	21	Discuss the generalisability (external validity) of the study results	19
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.